{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T07:21:06Z","timestamp":1793604066567,"version":"4.5.0"},"reference-count":259,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":55,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Reprod Health"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hormonal signals intricately regulate breast growth and development. Any perturbations due to altered endocrine and metabolic conditions, such as in polycystic ovary syndrome (PCOS), may influence breast cancer risk. This review highlights the susceptibility of women with PCOS to breast cancer, with\u00a0a focus on the potential contribution of its comorbidities, such as hyperandrogenism, obesity, insulin resistance, diabetes, menopausal status, inflammation, and use of ovulation induction agents to this association.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a narrative review including articles and information collected from PubMed, Scopus, Google Scholar, and the World Health Organization (WHO) websites. Studies were selected based on the availability of an abstract and research publication in English. Reports related to PCOS, its characteristics (hyperandrogenism, hyperinsulinemia, insulin resistance, type 2 diabetes, obesity), fertility treatment, and their association with breast cancer were included.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The interrelation between PCOS and breast carcinoma remains ambiguous due to inconsistent and inconclusive epidemiological evidence. The comorbidities associated with the condition are reported to collectively or individually influence this association. Women with PCOS present anovulatory cycles and have a high necessity of undergoing ovulation induction, further altering hormonal dynamics. Evidence in the literature suggests that the number of treatment cycles, age at the onset of treatment, and cumulative doses of agents used for ovulation induction are a few other factors that could affect breast cancer risk, though the results are inconclusive.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Existing literature suggests that PCOS and its characteristics may impact the process of breast development and possibly contribute to breast cancer, although the evidence is still conflicting. Moreover, temporary alterations of endocrine profile following fertility medications may have a significant influence on the breast cancer risk, although research has shown inconclusive evidence. Hence, robust experimental studies are required to understand the underlying mechanisms and the long-term health implications for women with PCOS due to the intricate association between these factors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12978-026-02355-4","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:24:42Z","timestamp":1779445482000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["PCOS and breast cancer risk: hormonal modulation and epidemiological trends"],"prefix":"10.1186","volume":"23","author":[{"given":"Jyolsna Ponnaratta","family":"Kunhiraman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reyon","family":"Dcunha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Venkatraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anujith","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satish Kumar","family":"Adiga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagarajan","family":"Kannan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guruprasad","family":"Kalthur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2355_CR1","unstructured":"WHO 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/polycystic-ovary-syndrome."},{"key":"2355_CR2","doi-asserted-by":"publisher","first-page":"261","DOI":"10.4103\/jhrs.JHRS_95_18","volume":"13","author":"R Deswal","year":"2020","unstructured":"Deswal R, Narwal V, Dang A, Pundir C. The prevalence of polycystic ovary syndrome: a brief systematic review. J Hum Reprod Sci. 2020;13:261. https:\/\/doi.org\/10.4103\/jhrs.JHRS_95_18.","journal-title":"J Hum Reprod Sci"},{"key":"2355_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1002\/ijgo.13125","volume":"149","author":"MA Ganie","year":"2020","unstructured":"Ganie MA, Rashid A, Sahu D, Nisar S, Wani IA, Khan J. Prevalence of polycystic ovary syndrome ( <scp>PCOS<\/scp> ) among reproductive age women from Kashmir Valley: a cross\u2010sectional study. Int J Gynaecol Obstet. 2020;149:231\u20136. https:\/\/doi.org\/10.1002\/ijgo.13125.","journal-title":"Int J Gynaecol Obstet"},{"key":"2355_CR4","doi-asserted-by":"publisher","first-page":"e2695","DOI":"10.1210\/clinem\/dgaa285","volume":"105","author":"H Cena","year":"2020","unstructured":"Cena H, Chiovato L, Nappi RE. Obesity, polycystic ovary syndrome, and infertility: a new avenue for GLP-1 receptor agonists. J Clin Endocrinol Metab. 2020;105:e2695\u2013709. https:\/\/doi.org\/10.1210\/clinem\/dgaa285.","journal-title":"J Clin Endocrinol Metab"},{"key":"2355_CR5","doi-asserted-by":"publisher","first-page":"e1071","DOI":"10.1210\/clinem\/dgaa839","volume":"106","author":"KM Hoeger","year":"2021","unstructured":"Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2021;106:e1071\u201383. https:\/\/doi.org\/10.1210\/clinem\/dgaa839.","journal-title":"J Clin Endocrinol Metab"},{"key":"2355_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1001\/jama.2021.4788","volume":"326","author":"SA Carson","year":"2021","unstructured":"Carson SA, Kallen AN. Diagnosis and management of infertility. JAMA. 2021;326:65. https:\/\/doi.org\/10.1001\/jama.2021.4788.","journal-title":"JAMA"},{"key":"2355_CR7","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1093\/humrep\/deab181","volume":"36","author":"S Palomba","year":"2021","unstructured":"Palomba S. Is fertility reduced in ovulatory women with polycystic ovary syndrome? An opinion paper. Hum Reprod. 2021;36:2421\u20138. https:\/\/doi.org\/10.1093\/humrep\/deab181.","journal-title":"Hum Reprod"},{"key":"2355_CR8","doi-asserted-by":"publisher","first-page":"R79","DOI":"10.1530\/REP-18-0583","volume":"158","author":"AP Snider","year":"2019","unstructured":"Snider AP, Wood JR. Obesity induces ovarian inflammation and reduces oocyte quality. Reproduction. 2019;158:R79-90. https:\/\/doi.org\/10.1530\/REP-18-0583.","journal-title":"Reproduction"},{"key":"2355_CR9","doi-asserted-by":"publisher","unstructured":"Barber TM, Hanson P, Weickert MO, Franks S. Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies. Clin Med Insights Reprod Health. 2019;13. https:\/\/doi.org\/10.1177\/1179558119874042.","DOI":"10.1177\/1179558119874042"},{"key":"2355_CR10","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1210\/jc.2015-3543","volume":"101","author":"M-ME Ollila","year":"2016","unstructured":"Ollila M-ME, Piltonen T, Puukka K, Ruokonen A, J\u00e4rvelin M-R, Tapanainen JS, et al. Weight gain and dyslipidemia in early adulthood associate with Polycystic Ovary Syndrome: Prospective cohort study. J Clin Endocrinol Metab. 2016;101:739\u201347. https:\/\/doi.org\/10.1210\/jc.2015-3543.","journal-title":"J Clin Endocrinol Metab"},{"key":"2355_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.tem.2016.11.008","volume":"28","author":"S Palomba","year":"2017","unstructured":"Palomba S, Daolio J, La Sala GB. Oocyte competence in women with polycystic ovary syndrome. Trends Endocrinol Metab. 2017;28:186\u201398. https:\/\/doi.org\/10.1016\/j.tem.2016.11.008.","journal-title":"Trends Endocrinol Metab"},{"key":"2355_CR12","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1093\/humupd\/dmaa051","volume":"27","author":"S Palomba","year":"2021","unstructured":"Palomba S, Piltonen TT, Giudice LC. Endometrial function in women with polycystic ovary syndrome: a comprehensive review. Hum Reprod Update. 2021;27:584\u2013618. https:\/\/doi.org\/10.1093\/humupd\/dmaa051.","journal-title":"Hum Reprod Update"},{"key":"2355_CR13","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/humupd\/dmv029","volume":"21","author":"S Palomba","year":"2015","unstructured":"Palomba S, de Wilde MA, Falbo A, Koster MPH, La Sala GB, Fauser BCJM. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21:575\u201392. https:\/\/doi.org\/10.1093\/humupd\/dmv029.","journal-title":"Hum Reprod Update"},{"key":"2355_CR14","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1093\/humrep\/deaa371","volume":"36","author":"J Liu","year":"2021","unstructured":"Liu J, Wu Q, Hao Y, Jiao M, Wang X, Jiang S, et al. Measuring the global disease burden of polycystic ovary syndrome in 194 countries: Global Burden of Disease Study 2017. Hum Reprod. 2021;36:1108\u201319. https:\/\/doi.org\/10.1093\/humrep\/deaa371.","journal-title":"Hum Reprod"},{"key":"2355_CR15","doi-asserted-by":"publisher","unstructured":"Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Eur J Endocrinol 2023;189:G43\u201364. https:\/\/doi.org\/10.1093\/ejendo\/lvad096.","DOI":"10.1093\/ejendo\/lvad096"},{"key":"2355_CR16","doi-asserted-by":"publisher","unstructured":"Teede HJ, Tay CT, Laven J, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Fertil Steril 2023;120:767\u201393. https:\/\/doi.org\/10.1016\/j.fertnstert.2023.07.025.","DOI":"10.1016\/j.fertnstert.2023.07.025"},{"key":"2355_CR17","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/s41390-019-0615-1","volume":"87","author":"SF Witchel","year":"2020","unstructured":"Witchel SF, Teede HJ, Pe\u00f1a AS. Curtailing PCOS. Pediatr Res. 2020;87:353\u201361. https:\/\/doi.org\/10.1038\/s41390-019-0615-1.","journal-title":"Pediatr Res"},{"key":"2355_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23073883","volume":"23","author":"SK Biswas","year":"2022","unstructured":"Biswas SK, Banerjee S, Baker GW, Kuo C-Y, Chowdhury I. The mammary gland: basic structure and molecular signaling during development. Int J Mol Sci. 2022;23:3883. https:\/\/doi.org\/10.3390\/ijms23073883.","journal-title":"Int J Mol Sci"},{"key":"2355_CR19","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0002-9378(97)80024-5","volume":"176","author":"G S\u00f6derqvist","year":"1997","unstructured":"S\u00f6derqvist G, Isaksson E, von Schoultz B, Carlstr\u00f6m K, Tani E, Skoog L. Proliferation of breast epithelial cells in healthy women during the menstrual cycle. Am J Obstet Gynecol. 1997;176:123\u20138. https:\/\/doi.org\/10.1016\/S0002-9378(97)80024-5.","journal-title":"Am J Obstet Gynecol"},{"key":"2355_CR20","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/bjc.1981.168","volume":"44","author":"DJ Ferguson","year":"1981","unstructured":"Ferguson DJ, Anderson TJ. Morphological evaluation of cell turnover in relation to the menstrual cycle in the \u201cresting\u201d human breast. Br J Cancer. 1981;44:177\u201381. https:\/\/doi.org\/10.1038\/bjc.1981.168.","journal-title":"Br J Cancer"},{"key":"2355_CR21","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1186\/bcr908","volume":"6","author":"C Streuli","year":"2004","unstructured":"Streuli C, Russo J, Russo IH. Molecular basis of breast cancer: Prevention and treatment. Breast Cancer Res. 2004;6:179. https:\/\/doi.org\/10.1186\/bcr908. (Berlin, Heidelberg, New York, Springer-Verlag.).","journal-title":"Breast Cancer Res"},{"key":"2355_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.mce.2017.08.011","volume":"466","author":"HN Hilton","year":"2018","unstructured":"Hilton HN, Clarke CL, Graham JD. Estrogen and progesterone signalling in the normal breast and its implications for cancer development. Mol Cell Endocrinol. 2018;466:2\u201314. https:\/\/doi.org\/10.1016\/j.mce.2017.08.011.","journal-title":"Mol Cell Endocrinol"},{"key":"2355_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s12935-022-02547-5","volume":"22","author":"P Kohnepoushi","year":"2022","unstructured":"Kohnepoushi P, Dehghanbanadaki H, Mohammadzedeh P, Nikouei M, Moradi Y. The effect of the polycystic ovary syndrome and hypothyroidism on the risk of fibrocystic breast changes: a meta-analysis. Cancer Cell Int. 2022;22:125. https:\/\/doi.org\/10.1186\/s12935-022-02547-5.","journal-title":"Cancer Cell Int"},{"key":"2355_CR24","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1080\/08998280.2024.2308458","volume":"37","author":"B Dang","year":"2024","unstructured":"Dang B, Clewis M, Miles B, Nguyen Q. The effect of polycystic ovarian syndrome on fibrocystic breast changes in postmenopausal women. Bayl Univ Med Cent Proc. 2024;37:432\u20136. https:\/\/doi.org\/10.1080\/08998280.2024.2308458.","journal-title":"Bayl Univ Med Cent Proc"},{"key":"2355_CR25","doi-asserted-by":"publisher","DOI":"10.1186\/s40738-016-0029-2","volume":"2","author":"HR Harris","year":"2016","unstructured":"Harris HR, Terry KL. Polycystic ovary syndrome and risk of endometrial, ovarian, and breast cancer: a systematic review. Fertil Res Pract. 2016;2:14. https:\/\/doi.org\/10.1186\/s40738-016-0029-2.","journal-title":"Fertil Res Pract"},{"key":"2355_CR26","doi-asserted-by":"publisher","first-page":"577","DOI":"10.18502\/ijrm.v17i8.4823","volume":"17","author":"B Eslami","year":"2019","unstructured":"Eslami B, Alipour S, Hosseini R, Fattah B, Moini A. Breast density in Polycystic Ovarian Syndrome patients: A case-control study. International Journal of Reproductive BioMedicine (IJRM). 2019;17:577\u201384. https:\/\/doi.org\/10.18502\/ijrm.v17i8.4823.","journal-title":"International Journal of Reproductive BioMedicine (IJRM)"},{"key":"2355_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s10552-016-0716-7","volume":"27","author":"J Kim","year":"2016","unstructured":"Kim J, Mersereau JE, Khankari N, Bradshaw PT, McCullough LE, Cleveland R, et al. Polycystic ovarian syndrome (PCOS), related symptoms\/sequelae, and breast cancer risk in a population-based case\u2013control study. Cancer Causes Control. 2016;27:403\u201314. https:\/\/doi.org\/10.1007\/s10552-016-0716-7.","journal-title":"Cancer Causes Control"},{"key":"2355_CR28","doi-asserted-by":"publisher","first-page":"367","DOI":"10.5468\/ogs.2016.59.5.367","volume":"59","author":"F Shobeiri","year":"2016","unstructured":"Shobeiri F, Jenabi E. The association between polycystic ovary syndrome and breast cancer: a meta-analysis. Obstet Gynecol Sci. 2016;59:367. https:\/\/doi.org\/10.5468\/ogs.2016.59.5.367.","journal-title":"Obstet Gynecol Sci"},{"key":"2355_CR29","doi-asserted-by":"publisher","unstructured":"Ghaempanah F, Sarabi SN, Sarabi SN, Gharahjeh S, Jamali K, Ahmadi S, et al. Polycystic Ovarian Syndrome and the Risk of Ovarian, Endometrial, and Breast Cancer: A Systematic Review and Meta-Analysis. Med J Islam Repub Iran 2025. https:\/\/doi.org\/10.47176\/mjiri.39.50.","DOI":"10.47176\/mjiri.39.50"},{"key":"2355_CR30","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1177\/00369330221107099","volume":"67","author":"Z Li","year":"2022","unstructured":"Li Z, Wang Y-H, Wang L-L, Hu D-T, Teng Y, Zhang T-Y, et al. Polycystic ovary syndrome and the risk of endometrial, ovarian and breast cancer: an updated meta-analysis. Scott Med J. 2022;67:109\u201320. https:\/\/doi.org\/10.1177\/00369330221107099.","journal-title":"Scott Med J"},{"key":"2355_CR31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1634\/theoncologist.2014-0311","volume":"20","author":"C-C Shen","year":"2015","unstructured":"Shen C-C, Yang AC, Hung J-H, Hu L-Y, Tsai S-J. A nationwide population-based retrospective cohort study of the risk of uterine, ovarian and breast cancer in women with polycystic ovary syndrome. Oncologist. 2015;20:45\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2014-0311.","journal-title":"Oncologist"},{"key":"2355_CR32","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000012608","volume":"97","author":"D-C Ding","year":"2018","unstructured":"Ding D-C, Chen W, Wang J-H, Lin S-Z. Association between polycystic ovarian syndrome and endometrial, ovarian, and breast cancer. Medicine. 2018;97:e12608. https:\/\/doi.org\/10.1097\/MD.0000000000012608.","journal-title":"Medicine"},{"key":"2355_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-93883-9","volume":"15","author":"Y Cai","year":"2025","unstructured":"Cai Y, Dai F, Ye Y, Qian J. The global burden of breast cancer among women of reproductive age: a comprehensive analysis. Sci Rep. 2025;15:9347. https:\/\/doi.org\/10.1038\/s41598-025-93883-9.","journal-title":"Sci Rep"},{"key":"2355_CR34","unstructured":"WHO. Breast cancer 2025. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer."},{"key":"2355_CR35","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349. https:\/\/doi.org\/10.3322\/caac.21660.","journal-title":"CA Cancer J Clin"},{"key":"2355_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/s41572-024-00511-3","volume":"10","author":"E Stener-Victorin","year":"2024","unstructured":"Stener-Victorin E, Teede H, Norman RJ, Legro R, Goodarzi MO, Dokras A, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2024;10:27. https:\/\/doi.org\/10.1038\/s41572-024-00511-3.","journal-title":"Nat Rev Dis Primers"},{"key":"2355_CR37","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.bpobgyn.2008.11.010","volume":"24","author":"S Papaioannou","year":"2010","unstructured":"Papaioannou S, Tzafettas J. Anovulation with or without PCO, hyperandrogenaemia and hyperinsulinaemia as promoters of endometrial and breast cancer. Best Pract Res Clin Obstet Gynaecol. 2010;24:19\u201327. https:\/\/doi.org\/10.1016\/j.bpobgyn.2008.11.010.","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"key":"2355_CR38","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1093\/humrep\/des042","volume":"27","author":"Z Haoula","year":"2012","unstructured":"Haoula Z, Salman M, Atiomo W. Evaluating the association between endometrial cancer and polycystic ovary syndrome. Hum Reprod. 2012;27:1327\u201331. https:\/\/doi.org\/10.1093\/humrep\/des042.","journal-title":"Hum Reprod"},{"key":"2355_CR39","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1111\/j.1600-0412.2012.01458.x","volume":"91","author":"NSL Holm","year":"2012","unstructured":"Holm NSL, Glintborg D, Andersen MS, Schledermann D, Ravn P. The prevalence of endometrial hyperplasia and endometrial cancer in women with polycystic ovary syndrome or hyperandrogenism. Acta Obstet Gynecol Scand. 2012;91:1173\u20136. https:\/\/doi.org\/10.1111\/j.1600-0412.2012.01458.x.","journal-title":"Acta Obstet Gynecol Scand"},{"key":"2355_CR40","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1093\/humupd\/dmu012","volume":"20","author":"JA Barry","year":"2014","unstructured":"Barry JA, Azizia MM, Hardiman PJ. Risk of endometrial, ovarian and breast cancer in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2014;20:748\u201358. https:\/\/doi.org\/10.1093\/humupd\/dmu012.","journal-title":"Hum Reprod Update"},{"key":"2355_CR41","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1002\/ijc.34574","volume":"153","author":"CLB Frandsen","year":"2023","unstructured":"Frandsen CLB, Svendsen PF, N\u00f8hr B, Viuff JH, Maltesen T, Kj\u00e6r SK, et al. Risk of epithelial ovarian tumors among women with polycystic ovary syndrome: a nationwide population\u2010based cohort study. Int J Cancer. 2023;153:958\u201368. https:\/\/doi.org\/10.1002\/ijc.34574.","journal-title":"Int J Cancer"},{"key":"2355_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1001\/jamaoncol.2018.5188","volume":"5","author":"W Yin","year":"2019","unstructured":"Yin W, Falconer H, Yin L, Xu L, Ye W. Association between polycystic ovary syndrome and cancer risk. JAMA Oncol. 2019;5:106. https:\/\/doi.org\/10.1001\/jamaoncol.2018.5188.","journal-title":"JAMA Oncol"},{"key":"2355_CR43","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s10654-018-0474-9","volume":"34","author":"FE Lundberg","year":"2019","unstructured":"Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Gemzell-Danielsson K, Johansson ALV. The risk of breast and gynecological cancer in women with a diagnosis of infertility: a nationwide population-based study. Eur J Epidemiol. 2019;34:499\u2013507. https:\/\/doi.org\/10.1007\/s10654-018-0474-9.","journal-title":"Eur J Epidemiol"},{"key":"2355_CR44","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/0029-7844(96)00226-8","volume":"88","author":"J Schildkraut","year":"1996","unstructured":"Schildkraut J. Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol. 1996;88:554\u20139. https:\/\/doi.org\/10.1016\/0029-7844(96)00226-8.","journal-title":"Obstet Gynecol"},{"key":"2355_CR45","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/ije\/dyz113","volume":"48","author":"HR Harris","year":"2019","unstructured":"Harris HR, Cushing-Haugen KL, Webb PM, Nagle CM, Jordan SJ, Risch HA, et al. Association between genetically predicted polycystic ovary syndrome and ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2019;48:822\u201330. https:\/\/doi.org\/10.1093\/ije\/dyz113.","journal-title":"Int J Epidemiol"},{"key":"2355_CR46","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.ejogrb.2024.06.031","volume":"299","author":"A Abu-Zaid","year":"2024","unstructured":"Abu-Zaid A, Baradwan S, Alyafi M, Al Baalharith M, Alsehaimi SO, Alsabban M, et al. Association between Polycystic Ovary Syndrome and the risk of malignant gynecologic cancers (ovarian, endometrial, and cervical): A population-based study from the U.S.A. National Inpatient Sample 2016\u20132019. Eur J Obstet Gynecol Reprod Biol. 2024;299:283\u20138. https:\/\/doi.org\/10.1016\/j.ejogrb.2024.06.031.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2355_CR47","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ygyno.2014.11.012","volume":"136","author":"M Gottschau","year":"2015","unstructured":"Gottschau M, Kjaer SK, Jensen A, Munk C, Mellemkjaer L. Risk of cancer among women with polycystic ovary syndrome: a Danish cohort study. Gynecol Oncol. 2015;136:99\u2013103. https:\/\/doi.org\/10.1016\/j.ygyno.2014.11.012.","journal-title":"Gynecol Oncol"},{"key":"2355_CR48","doi-asserted-by":"publisher","unstructured":"McAllister JM, Modi B, Miller BA, Biegler J, Bruggeman R, Legro RS, et al. Overexpression of a DENND1A isoform produces a polycystic ovary syndrome theca phenotype. Proceedings of the National Academy of Sciences 2014;111. https:\/\/doi.org\/10.1073\/pnas.1400574111.","DOI":"10.1073\/pnas.1400574111"},{"key":"2355_CR49","doi-asserted-by":"publisher","first-page":"e899","DOI":"10.1210\/clinem\/dgab757","volume":"107","author":"T Zhu","year":"2022","unstructured":"Zhu T, Goodarzi MO. Causes and consequences of polycystic ovary syndrome: insights from Mendelian randomization. J Clin Endocrinol Metab. 2022;107:e899-911. https:\/\/doi.org\/10.1210\/clinem\/dgab757.","journal-title":"J Clin Endocrinol Metab"},{"key":"2355_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-022-01782-2","volume":"22","author":"MS Butt","year":"2022","unstructured":"Butt MS, Saleem J, Aiman S, Zakar R, Sadique I, Fischer F. Serum anti-M\u00fcllerian hormone as a predictor of polycystic ovarian syndrome among women of reproductive age. BMC Womens Health. 2022;22:199. https:\/\/doi.org\/10.1186\/s12905-022-01782-2.","journal-title":"BMC Womens Health"},{"key":"2355_CR51","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s43043-022-00123-5","volume":"27","author":"K Bhattacharya","year":"2022","unstructured":"Bhattacharya K, Saha I, Sen D, Bose C, Chaudhuri GR, Dutta S, et al. Role of anti-Mullerian hormone in polycystic ovary syndrome. Middle East Fertil Soc J. 2022;27:32. https:\/\/doi.org\/10.1186\/s43043-022-00123-5.","journal-title":"Middle East Fertil Soc J"},{"key":"2355_CR52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/S0303-7207(02)00105-3","volume":"193","author":"S And\u00f2","year":"2002","unstructured":"And\u00f2 S, De Amicis F, Rago V, Carpino A, Maggiolini M, Panno ML, et al. Breast cancer: from estrogen to androgen receptor. Mol Cell Endocrinol. 2002;193:121\u20138. https:\/\/doi.org\/10.1016\/S0303-7207(02)00105-3.","journal-title":"Mol Cell Endocrinol"},{"key":"2355_CR53","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1210\/er.2003-0016","volume":"25","author":"W Somboonporn","year":"2004","unstructured":"Somboonporn W, Davis SR. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr Rev. 2004;25:374\u201388. https:\/\/doi.org\/10.1210\/er.2003-0016.","journal-title":"Endocr Rev"},{"key":"2355_CR54","doi-asserted-by":"publisher","first-page":"R81","DOI":"10.1530\/ERC-18-0429","volume":"26","author":"G Secreto","year":"2019","unstructured":"Secreto G, Girombelli A, Krogh V. Androgen excess in breast cancer development: implications for prevention and treatment. Endocr-Relat Cancer. 2019;26:R81-94. https:\/\/doi.org\/10.1530\/ERC-18-0429.","journal-title":"Endocr-Relat Cancer"},{"key":"2355_CR55","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1093\/ije\/dyz107","volume":"48","author":"NL Dimou","year":"2019","unstructured":"Dimou NL, Papadimitriou N, Gill D, Christakoudi S, Murphy N, Gunter MJ, et al. Sex hormone binding globulin and risk of breast cancer: a Mendelian randomization study. Int J Epidemiol. 2019;48:807\u201316. https:\/\/doi.org\/10.1093\/ije\/dyz107.","journal-title":"Int J Epidemiol"},{"key":"2355_CR56","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1002\/ijc.31249","volume":"142","author":"W Ge","year":"2018","unstructured":"Ge W, Clendenen TV, Afanasyeva Y, Koenig KL, Agnoli C, Brinton LA, et al. Circulating anti\u2010M\u00fcllerian hormone and breast cancer risk: a study in ten prospective cohorts. Int J Cancer. 2018;142:2215\u201326. https:\/\/doi.org\/10.1002\/ijc.31249.","journal-title":"Int J Cancer"},{"key":"2355_CR57","doi-asserted-by":"publisher","unstructured":"Chen X, Liu S, Peng X, Zong X. The roles of anti-M\u00fcllerian hormone in breast cancer. Endocr Relat Cancer 2023;30. https:\/\/doi.org\/10.1530\/ERC-23-0060.","DOI":"10.1530\/ERC-23-0060"},{"key":"2355_CR58","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1016\/S1472-6483(10)60175-7","volume":"19","author":"B Chittenden","year":"2009","unstructured":"Chittenden B, Fullerton G, Maheshwari A, Bhattacharya S. Polycystic ovary syndrome and the risk of gynaecological cancer: a systematic review. Reprod Biomed Online. 2009;19:398\u2013405. https:\/\/doi.org\/10.1016\/S1472-6483(10)60175-7.","journal-title":"Reprod Biomed Online"},{"key":"2355_CR59","doi-asserted-by":"publisher","first-page":"893","DOI":"10.18502\/ijrm.v20i11.12357","volume":"20","author":"M Amiri","year":"2022","unstructured":"Amiri M, Bidhendi-Yarandi R, Fallahzadeh A, Marzban Z, Ramezani Tehrani F. Risk of endometrial, ovarian, and breast cancers in women with polycystic ovary syndrome: a systematic review and meta-analysis. International Journal of Reproductive BioMedicine (IJRM). 2022;20:893\u2013914. https:\/\/doi.org\/10.18502\/ijrm.v20i11.12357.","journal-title":"International Journal of Reproductive BioMedicine (IJRM)"},{"key":"2355_CR60","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1007\/s10549-024-07467-8","volume":"208","author":"CLB Frandsen","year":"2024","unstructured":"Frandsen CLB, N\u00f8hr B, Gottschau M, Viuff JH, Maltesen T, Kj\u00e6r SK, et al. Polycystic ovary syndrome and risk of breast cancer in premenopausal and postmenopausal women: a nationwide population-based cohort study. Breast Cancer Res Treat. 2024;208:535\u201342. https:\/\/doi.org\/10.1007\/s10549-024-07467-8.","journal-title":"Breast Cancer Res Treat"},{"key":"2355_CR61","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/1464727002000198781","volume":"3","author":"S Wild","year":"2000","unstructured":"Wild S, Pierpoint T, Jacobs H, McKeigue P. Long-term consequences of polycystic ovary syndrome: results of a 31 year follow-up study. Hum Fertil. 2000;3:101\u20135. https:\/\/doi.org\/10.1080\/1464727002000198781.","journal-title":"Hum Fertil"},{"key":"2355_CR62","first-page":"285","volume":"28","author":"GM Calaf","year":"2006","unstructured":"Calaf GM. Susceptibility of human breast epithelial cells in vitro to hormones and drugs. Int J Oncol. 2006;28:285\u201395.","journal-title":"Int J Oncol"},{"key":"2355_CR63","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1093\/carcin\/20.6.1069","volume":"20","author":"B Xie","year":"1999","unstructured":"Xie B, Tsao S, Wong YC. Induction of high incidence of mammary tumour in female Noble rats with a combination of 17-oestradiol and testosterone. Carcinogenesis. 1999;20:1069\u201378. https:\/\/doi.org\/10.1093\/carcin\/20.6.1069.","journal-title":"Carcinogenesis"},{"key":"2355_CR64","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1080\/09513590.2019.1576613","volume":"35","author":"M Noroozzadeh","year":"2019","unstructured":"Noroozzadeh M, Behboudi-Gandevani S, Mosaffa N, Tohidi M, Ramezani Tehrani F. High prevalence of benign mammary tumors in a rat model of polycystic ovary syndrome during postmenopausal period. Gynecol Endocrinol. 2019;35:679\u201384. https:\/\/doi.org\/10.1080\/09513590.2019.1576613.","journal-title":"Gynecol Endocrinol"},{"key":"2355_CR65","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1097\/GRF.0000000000000239","volume":"59","author":"K Rojas","year":"2016","unstructured":"Rojas K, Stuckey A. Breast cancer epidemiology and risk factors. Clin Obstet Gynecol. 2016;59:651\u201372. https:\/\/doi.org\/10.1097\/GRF.0000000000000239.","journal-title":"Clin Obstet Gynecol"},{"key":"2355_CR66","first-page":"1061","volume":"12","author":"S Liao","year":"2011","unstructured":"Liao S, Li J, Wei W, Wang L, Zhang Y, Li J, et al. Association between diabetes mellitus and breast cancer risk: a meta-analysis of the literature. Asian Pac J Cancer Prev. 2011;12:1061\u20135.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2355_CR67","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1080\/13813450801954451","volume":"114","author":"P Pisani","year":"2008","unstructured":"Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem. 2008;114:63\u201370. https:\/\/doi.org\/10.1080\/13813450801954451.","journal-title":"Arch Physiol Biochem"},{"key":"2355_CR68","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/j.1467-789X.2004.00142.x","volume":"5","author":"DP Rose","year":"2004","unstructured":"Rose DP, Komninou D, Stephenson GD. Obesity, adipocytokines, and insulin resistance in breast cancer. Obes Rev. 2004;5:153\u201365. https:\/\/doi.org\/10.1111\/j.1467-789X.2004.00142.x.","journal-title":"Obes Rev"},{"key":"2355_CR69","doi-asserted-by":"publisher","DOI":"10.1186\/s12905-023-02543-5","volume":"23","author":"T Dehesh","year":"2023","unstructured":"Dehesh T, Fadaghi S, Seyedi M, Abolhadi E, Ilaghi M, Shams P, et al. The relation between obesity and breast cancer risk in women by considering menstruation status and geographical variations: a systematic review and meta-analysis. BMC Womens Health. 2023;23:392. https:\/\/doi.org\/10.1186\/s12905-023-02543-5.","journal-title":"BMC Womens Health"},{"key":"2355_CR70","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1007\/s10552-013-0181-5","volume":"24","author":"M Kawai","year":"2013","unstructured":"Kawai M, Kakugawa Y, Nishino Y, Hamanaka Y, Ohuchi N, Minami Y. Anthropometric factors, physical activity, and breast cancer risk in relation to hormone receptor and menopausal status in Japanese women: a case\u2013control study. Cancer Causes Control. 2013;24:1033\u201344. https:\/\/doi.org\/10.1007\/s10552-013-0181-5.","journal-title":"Cancer Causes Control"},{"key":"2355_CR71","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/S0140-6736(08)60269-X","volume":"371","author":"AG Renehan","year":"2008","unstructured":"Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569\u201378. https:\/\/doi.org\/10.1016\/S0140-6736(08)60269-X.","journal-title":"Lancet"},{"key":"2355_CR72","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.seminoncol.2017.11.002","volume":"44","author":"AJ Abdelwahab Yousef","year":"2017","unstructured":"Abdelwahab Yousef AJ. Male breast cancer: epidemiology and risk factors. Semin Oncol. 2017;44:267\u201372. https:\/\/doi.org\/10.1053\/j.seminoncol.2017.11.002.","journal-title":"Semin Oncol"},{"key":"2355_CR73","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.7150\/ijbs.21635","volume":"13","author":"Y-S Sun","year":"2017","unstructured":"Sun Y-S, Zhao Z, Yang Z-N, Xu F, Lu H-J, Zhu Z-Y, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017;13:1387\u201397. https:\/\/doi.org\/10.7150\/ijbs.21635.","journal-title":"Int J Biol Sci"},{"key":"2355_CR74","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-019-1096-1","volume":"21","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Xia J, Li L, Ke Y, Cheng J, Xie Y, et al. Associations between dietary patterns and the risk of breast cancer: a systematic review and meta-analysis of observational studies. Breast Cancer Res. 2019;21:16. https:\/\/doi.org\/10.1186\/s13058-019-1096-1.","journal-title":"Breast Cancer Res"},{"key":"2355_CR75","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.beem.2005.09.007","volume":"20","author":"PD Darbre","year":"2006","unstructured":"Darbre PD. Environmental oestrogens, cosmetics and breast cancer. Best Pract Res Clin Endocrinol Metab. 2006;20:121\u201343. https:\/\/doi.org\/10.1016\/j.beem.2005.09.007.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2355_CR76","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1023\/B:CACO.0000036167.51236.86","volume":"15","author":"j ibarluzea","year":"2004","unstructured":"ibarluzea j, Fern\u00e1ndez MF, Santa-Marina L, Olea-Serrano MF, Rivas AM, Aurrekoetxea JJ, et al. Breast cancer risk and the combined effect of environmental estrogens. Cancer Causes Control. 2004;15:591\u2013600. https:\/\/doi.org\/10.1023\/B:CACO.0000036167.51236.86.","journal-title":"Cancer Causes Control"},{"key":"2355_CR77","doi-asserted-by":"publisher","first-page":"s18","DOI":"10.1210\/en.2005-1131","volume":"147","author":"SE Fenton","year":"2006","unstructured":"Fenton SE. Endocrine-disrupting compounds and mammary gland development: early exposure and later life consequences. Endocrinology. 2006;147:s18-24. https:\/\/doi.org\/10.1210\/en.2005-1131.","journal-title":"Endocrinology"},{"key":"2355_CR78","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.7314\/APJCP.2015.16.7.2857","volume":"16","author":"Y Kim","year":"2015","unstructured":"Kim Y, Yoo K-Y, Goodman MT. Differences in incidence, mortality and survival of breast cancer by regions and countries in Asia and contributing factors. Asian Pac J Cancer Prev. 2015;16:2857\u201370. https:\/\/doi.org\/10.7314\/APJCP.2015.16.7.2857.","journal-title":"Asian Pac J Cancer Prev"},{"key":"2355_CR79","doi-asserted-by":"publisher","first-page":"106","DOI":"10.4103\/sajc.sajc_157_16","volume":"06","author":"P Thakur","year":"2017","unstructured":"Thakur P, Seam RK, Gupta MK, Gupta M, Sharma M, Fotedar V. Breast cancer risk factor evaluation in a Western Himalayan state: a case\u2013control study and comparison with the Western World. South Asian J Cancer. 2017;06:106\u20139. https:\/\/doi.org\/10.4103\/sajc.sajc_157_16.","journal-title":"South Asian J Cancer"},{"key":"2355_CR80","doi-asserted-by":"publisher","unstructured":"Laamiri FZ, Hasswane N, Kerbach A, Aguenaou H, Taboz Y, Benkirane H, et al. Risk factors associated with a breast cancer in a population of Moroccan women whose age is less than 40 years: a case control study. Pan African Medical Journal 2016;24. https:\/\/doi.org\/10.11604\/pamj.2016.24.19.8784.","DOI":"10.11604\/pamj.2016.24.19.8784"},{"key":"2355_CR81","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1677\/erc.1.01038","volume":"12","author":"R Kaaks","year":"2005","unstructured":"Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PHM, Biessy C, et al. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer. 2005;12:1071\u201382. https:\/\/doi.org\/10.1677\/erc.1.01038.","journal-title":"Endocr Relat Cancer"},{"key":"2355_CR82","doi-asserted-by":"publisher","unstructured":"Dall GV, Britt KL. Estrogen Effects on the Mammary Gland in Early and Late Life and Breast Cancer Risk. Front Oncol. 2017;7. https:\/\/doi.org\/10.3389\/fonc.2017.00110.","DOI":"10.3389\/fonc.2017.00110"},{"key":"2355_CR83","doi-asserted-by":"publisher","first-page":"265","DOI":"10.2147\/IJWH.S129017","volume":"9","author":"J Horn","year":"2017","unstructured":"Horn J, Vatten L. Reproductive and hormonal risk factors of breast cancer: a historical perspective. Int J Womens Health. 2017;9:265\u201372. https:\/\/doi.org\/10.2147\/IJWH.S129017.","journal-title":"Int J Womens Health"},{"key":"2355_CR84","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.breast.2017.07.017","volume":"35","author":"S Paluch-Shimon","year":"2017","unstructured":"Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso M-J, Dent RA, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203\u201317. https:\/\/doi.org\/10.1016\/j.breast.2017.07.017.","journal-title":"Breast"},{"key":"2355_CR85","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.3892\/ol.2013.1516","volume":"6","author":"J Zhou","year":"2013","unstructured":"Zhou J, Chen Y, Huang Y, Long J, Wan F, Zhang S. Serum follicle-stimulating hormone level is associated with human epidermal growth factor receptor type 2 and Ki67 expression in post-menopausal females with breast cancer. Oncol Lett. 2013;6:1128\u201332. https:\/\/doi.org\/10.3892\/ol.2013.1516.","journal-title":"Oncol Lett"},{"key":"2355_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002201","volume":"13","author":"C Lefebvre","year":"2016","unstructured":"Lefebvre C, Bachelot T, Filleron T, Pedrero M, Campone M, Soria J-C, et al. Mutational profile of metastatic breast cancers: a retrospective analysis. PLoS Med. 2016;13:e1002201. https:\/\/doi.org\/10.1371\/journal.pmed.1002201.","journal-title":"PLoS Med"},{"key":"2355_CR87","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1002\/mc.22565","volume":"56","author":"MR Roberts","year":"2017","unstructured":"Roberts MR, Sucheston-Campbell LE, Zirpoli GR, Higgins M, Freudenheim JL, Bandera EV, et al. Single nucleotide variants in metastasis-related genes are associated with breast cancer risk, by lymph node involvement and estrogen receptor status, in women with European and African ancestry. Mol Carcinog. 2017;56:1000\u20139. https:\/\/doi.org\/10.1002\/mc.22565.","journal-title":"Mol Carcinog"},{"key":"2355_CR88","doi-asserted-by":"publisher","unstructured":"Varna M, Bousquet G, Plassa L-F, Bertheau P, Janin A. TP53 Status and Response to Treatment in Breast Cancers. Biomed Res Int. 2011;2011. https:\/\/doi.org\/10.1155\/2011\/284584.","DOI":"10.1155\/2011\/284584"},{"key":"2355_CR89","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.1158\/1078-0432.CCR-15-0965","volume":"22","author":"S Loibl","year":"2016","unstructured":"Loibl S, Darb-Esfahani S, Huober J, Klimowicz A, Furlanetto J, Lederer B, et al. Integrated analysis of PTEN and p4EBP1 protein expression as predictors for pCR in HER2-positive breast cancer. Clin Cancer Res. 2016;22:2675\u201383. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-0965.","journal-title":"Clin Cancer Res"},{"key":"2355_CR90","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2024.100541","volume":"37","author":"CJ Schwartz","year":"2024","unstructured":"Schwartz CJ, Marra A, Selenica P, Gazzo A, Tan K, Ross D, et al. RB1 genetic alterations in estrogen receptor-positive breast carcinomas: correlation with neuroendocrine differentiation. Mod Pathol. 2024;37:100541. https:\/\/doi.org\/10.1016\/j.modpat.2024.100541.","journal-title":"Mod Pathol"},{"key":"2355_CR91","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1158\/1535-7163.MCT-15-0945","volume":"15","author":"M Choi","year":"2016","unstructured":"Choi M, Kipps T, Kurzrock R. ATM mutations in cancer: therapeutic implications. Mol Cancer Ther. 2016;15:1781\u201391. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0945.","journal-title":"Mol Cancer Ther"},{"key":"2355_CR92","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ijc.20403","volume":"112","author":"A Micheli","year":"2004","unstructured":"Micheli A, Muti P, Secreto G, Krogh V, Meneghini E, Venturelli E, et al. Endogenous sex hormones and subsequent breast cancer in premenopausal women. Int J Cancer. 2004;112:312\u20138. https:\/\/doi.org\/10.1002\/ijc.20403.","journal-title":"Int J Cancer"},{"key":"2355_CR93","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1093\/jnci\/dji132","volume":"97","author":"R Kaaks","year":"2005","unstructured":"Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, et al. Serum sex steroids in premenopausal women and breast cancer risk within the European prospective investigation into cancer and nutrition (EPIC). JNCI J Natl Cancer Inst. 2005;97:755\u201365. https:\/\/doi.org\/10.1093\/jnci\/dji132.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2355_CR94","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1158\/1055-9965.EPI-05-0976","volume":"15","author":"SS Tworoger","year":"2006","unstructured":"Tworoger SS, Missmer SA, Eliassen AH, Spiegelman D, Folkerd E, Dowsett M, et al. The association of plasma DHEA and DHEA sulfate with breast cancer risk in predominantly premenopausal women. Cancer Epidemiol Biomarkers Prev. 2006;15:967\u201371. https:\/\/doi.org\/10.1158\/1055-9965.EPI-05-0976.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2355_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2779","volume":"12","author":"JF Dorgan","year":"2010","unstructured":"Dorgan JF, Stanczyk FZ, Kahle LL, Brinton LA. Prospective case-control study of premenopausal serum estradiol and testosterone levels and breast cancer risk. Breast Cancer Res. 2010;12:R98. https:\/\/doi.org\/10.1186\/bcr2779.","journal-title":"Breast Cancer Res"},{"key":"2355_CR96","doi-asserted-by":"publisher","first-page":"3400","DOI":"10.1210\/jc.2015-2123","volume":"100","author":"P Pinola","year":"2015","unstructured":"Pinola P, Piltonen TT, Puurunen J, Vanky E, Sundstr\u00f6m-Poromaa I, Stener-Victorin E, et al. Androgen profile through life in women with Polycystic Ovary Syndrome: a Nordic multicenter collaboration study. J Clin Endocrinol Metab. 2015;100:3400\u20137. https:\/\/doi.org\/10.1210\/jc.2015-2123.","journal-title":"J Clin Endocrinol Metab"},{"key":"2355_CR97","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1023\/A:1013796112348","volume":"12","author":"JA Baron","year":"2001","unstructured":"Baron JA, Weiderpass E, Newcomb PA, Stampfer M, Titus-Ernstoff L, Egan KM, et al. Metabolic disorders and breast cancer risk (United States). Cancer Causes Control. 2001;12:875\u201380. https:\/\/doi.org\/10.1023\/A:1013796112348.","journal-title":"Cancer Causes Control"},{"key":"2355_CR98","doi-asserted-by":"publisher","unstructured":"Endogenous Hormones and Breast Cancer Collaborative Group, Key TJ, Appleby PN, Reeves GK, Travis RC, Alberg AJ, et al. Sex hormones and risk of breast cancer in premenopausal women: a collaborative reanalysis of individual participant data from seven prospective studies. Lancet Oncol 2013;14:1009\u201319. https:\/\/doi.org\/10.1016\/S1470-2045(13)70301-2.","DOI":"10.1016\/S1470-2045(13)70301-2"},{"key":"2355_CR99","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1530\/ERC-11-0310","volume":"19","author":"E-O Fourkala","year":"2012","unstructured":"Fourkala E-O, Zaikin A, Burnell M, Gentry-Maharaj A, Ford J, Gunu R, et al. Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocr Relat Cancer. 2012;19:137\u201347. https:\/\/doi.org\/10.1530\/ERC-11-0310.","journal-title":"Endocr Relat Cancer"},{"key":"2355_CR100","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1677\/ERC-09-0211","volume":"17","author":"CG Woolcott","year":"2010","unstructured":"Woolcott CG, Shvetsov YB, Stanczyk FZ, Wilkens LR, White KK, Caberto C, et al. Plasma sex hormone concentrations and breast cancer risk in an ethnically diverse population of postmenopausal women: the Multiethnic Cohort Study. Endocr Relat Cancer. 2010;17:125\u201334. https:\/\/doi.org\/10.1677\/ERC-09-0211.","journal-title":"Endocr Relat Cancer"},{"key":"2355_CR101","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1002\/ijc.26071","volume":"130","author":"S Sieri","year":"2012","unstructured":"Sieri S, Muti P, Claudia A, Berrino F, Pala V, Grioni S, et al. Prospective study on the role of glucose metabolism in breast cancer occurrence. Int J Cancer. 2012;130:921\u20139. https:\/\/doi.org\/10.1002\/ijc.26071.","journal-title":"Int J Cancer"},{"key":"2355_CR102","doi-asserted-by":"publisher","unstructured":"Srinivasan M, Arzoun H, GK LB, Thangaraj SR. A Systematic Review: Does Insulin Resistance Affect the Risk and Survival Outcome of Breast Cancer in Women? Cureus 2022. https:\/\/doi.org\/10.7759\/cureus.21712.","DOI":"10.7759\/cureus.21712"},{"key":"2355_CR103","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1002\/ijc.22717","volume":"121","author":"SC Larsson","year":"2007","unstructured":"Larsson SC, Mantzoros CS, Wolk A. Diabetes mellitus and risk of breast cancer: a meta\u2010analysis. Int J Cancer. 2007;121:856\u201362. https:\/\/doi.org\/10.1002\/ijc.22717.","journal-title":"Int J Cancer"},{"key":"2355_CR104","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1038\/bjc.2012.414","volume":"107","author":"P Boyle","year":"2012","unstructured":"Boyle P, Boniol M, Koechlin A, Robertson C, Valentini F, Coppens K, et al. Diabetes and breast cancer risk: a meta-analysis. Br J Cancer. 2012;107:1608\u201317. https:\/\/doi.org\/10.1038\/bjc.2012.414.","journal-title":"Br J Cancer"},{"key":"2355_CR105","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1530\/ERC-12-0242","volume":"19","author":"PJ Hardefeldt","year":"2012","unstructured":"Hardefeldt PJ, Edirimanne S, Eslick GD. Diabetes increases the risk of breast cancer: a meta-analysis. Endocr Relat Cancer. 2012;19:793\u2013803. https:\/\/doi.org\/10.1530\/ERC-12-0242.","journal-title":"Endocr Relat Cancer"},{"key":"2355_CR106","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1038\/bjc.1997.289","volume":"75","author":"R Talamini","year":"1997","unstructured":"Talamini R, Franceschi S, Favero A, Negri E, Parazzini F, La Vecchia C. Selected medical conditions and risk of breast cancer. Br J Cancer. 1997;75:1699\u2013703. https:\/\/doi.org\/10.1038\/bjc.1997.289.","journal-title":"Br J Cancer"},{"key":"2355_CR107","first-page":"2334","volume":"6","author":"W Sun","year":"2016","unstructured":"Sun W, Lu J, Wu S, Bi Y, Mu Y, Zhao J, et al. Association of insulin resistance with breast, ovarian, endometrial and cervical cancers in non-diabetic women. Am J Cancer Res. 2016;6:2334\u201344.","journal-title":"Am J Cancer Res"},{"key":"2355_CR108","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1002\/ijc.2910520402","volume":"52","author":"PF Bruning","year":"1992","unstructured":"Bruning PF, Bonfr\u00e8r JMG, van Noord PAH, Hart AAM, de Jong\u2010Bakker M, Nooijen WJ. Insulin resistance and breast\u2010cancer risk. Int J Cancer. 1992;52:511\u20136. https:\/\/doi.org\/10.1002\/ijc.2910520402.","journal-title":"Int J Cancer"},{"key":"2355_CR109","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1093\/jnci\/djn415","volume":"101","author":"MJ Gunter","year":"2009","unstructured":"Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, et al. Insulin, Insulin-Like Growth Factor-I, and risk of breast cancer in postmenopausal women. JNCI J Natl Cancer Inst. 2009;101:48\u201360. https:\/\/doi.org\/10.1093\/jnci\/djn415.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2355_CR110","doi-asserted-by":"publisher","first-page":"R225","DOI":"10.1530\/ERC-12-0203","volume":"19","author":"DP Rose","year":"2012","unstructured":"Rose DP, Vona-Davis L. The cellular and molecular mechanisms by which insulin influences breast cancer risk and progression. Endocr Relat Cancer. 2012;19:R225\u201341. https:\/\/doi.org\/10.1530\/ERC-12-0203.","journal-title":"Endocr Relat Cancer"},{"key":"2355_CR111","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1158\/0008-5472.CAN-09-2141","volume":"70","author":"R Novosyadlyy","year":"2010","unstructured":"Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y, et al. Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of Type 2 Diabetes. Cancer Res. 2010;70:741\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-09-2141.","journal-title":"Cancer Res"},{"key":"2355_CR112","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0170084","volume":"12","author":"HK Bronsveld","year":"2017","unstructured":"Bronsveld HK, Jensen V, Vahl P, De Bruin ML, Cornelissen S, Sanders J, et al. Diabetes and breast cancer subtypes. PLoS ONE. 2017;12:e0170084. https:\/\/doi.org\/10.1371\/journal.pone.0170084.","journal-title":"PLoS ONE"},{"key":"2355_CR113","doi-asserted-by":"publisher","first-page":"1823","DOI":"10.1093\/humrep\/deae124","volume":"39","author":"D Glintborg","year":"2024","unstructured":"Glintborg D, Ollila M-M, M\u00f8ller J-JK, Pesonen P, Persson S, Elenis E, et al. Prospective risk of type 2 diabetes in 99\u00a0892 Nordic women with polycystic ovary syndrome and 446\u00a0055 controls: national cohort study from Denmark, Finland, and Sweden. Hum Reprod. 2024;39:1823\u201334. https:\/\/doi.org\/10.1093\/humrep\/deae124.","journal-title":"Hum Reprod"},{"key":"2355_CR114","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/humupd\/dmy007","volume":"24","author":"NS Kakoly","year":"2018","unstructured":"Kakoly NS, Khomami MB, Joham AE, Cooray SD, Misso ML, Norman RJ, et al. Ethnicity, obesity and the prevalence of impaired glucose tolerance and Type 2 Diabetes in PCOS: a systematic review and meta-regression. Hum Reprod Update. 2018;24:455\u201367. https:\/\/doi.org\/10.1093\/humupd\/dmy007.","journal-title":"Hum Reprod Update"},{"key":"2355_CR115","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/6869705","volume":"2018","author":"B Zhang","year":"2018","unstructured":"Zhang B, Wang J, Shen S, Liu J, Sun J, Gu T, et al. Association of androgen excess with glucose intolerance in women with polycystic ovary syndrome. Biomed Res Int. 2018;2018:1\u20138. https:\/\/doi.org\/10.1155\/2018\/6869705.","journal-title":"Biomed Res Int"},{"key":"2355_CR116","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-023-01306-y","volume":"16","author":"R Cao","year":"2023","unstructured":"Cao R, Chen L, Liu Y, Wang X, Ma R, Zhao Q, et al. Causal pathways linking polycystic ovary syndrome to distinct breast cancer subtypes through mediator factors: a multivariable Mendelian randomization analysis. J Ovarian Res. 2023;16:215. https:\/\/doi.org\/10.1186\/s13048-023-01306-y.","journal-title":"J Ovarian Res"},{"key":"2355_CR117","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000036831","volume":"103","author":"N Tzenios","year":"2024","unstructured":"Tzenios N, Tazanios ME, Chahine M. The impact of BMI on breast cancer \u2013 an updated systematic review and meta-analysis. Medicine Baltimore. 2024;103:e36831. https:\/\/doi.org\/10.1097\/MD.0000000000036831.","journal-title":"Medicine Baltimore"},{"key":"2355_CR118","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-025-01961-7","volume":"27","author":"M Gaber","year":"2025","unstructured":"Gaber M, Quentel A, Holmes J, Lepetit C, Triki H, Wilson A, et al. Obesity increases DNA damage in the breast epithelium. Breast Cancer Res. 2025;27:11. https:\/\/doi.org\/10.1186\/s13058-025-01961-7.","journal-title":"Breast Cancer Res"},{"key":"2355_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2025.100965","volume":"44","author":"A Motuma","year":"2025","unstructured":"Motuma A, Mussa I, Deressa A, Regassa LD, Birhanu A. Central obesity increases the risk of breast cancer irrespective of menopausal status in women: systematic review and meta-analysis. Cancer Treat Res Commun. 2025;44:100965. https:\/\/doi.org\/10.1016\/j.ctarc.2025.100965.","journal-title":"Cancer Treat Res Commun"},{"key":"2355_CR120","doi-asserted-by":"publisher","DOI":"10.3390\/cells8121499","volume":"8","author":"R Sarfstein","year":"2019","unstructured":"Sarfstein R, Nagaraj K, LeRoith D, Werner H. Differential effects of insulin and IGF1 receptors on ERK and AKT subcellular distribution in breast cancer cells. Cells. 2019;8:1499. https:\/\/doi.org\/10.3390\/cells8121499.","journal-title":"Cells"},{"key":"2355_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1093257","author":"W Zhong","year":"2023","unstructured":"Zhong W, Wang X, Wang Y, Sun G, Zhang J, Li Z. Obesity and endocrine-related cancer: the important role of IGF-1. Front Endocrinol (Lausanne). 2023. https:\/\/doi.org\/10.3389\/fendo.2023.1093257.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2355_CR122","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.21846","volume":"7","author":"SK Sudan","year":"2024","unstructured":"Sudan SK, Sharma A, Vikramdeo KS, Davis W, Deshmukh SK, Poosarla T, et al. Obesity and early-onset breast cancer and specific molecular subtype diagnosis in Black and White women. JAMA Netw Open. 2024;7:e2421846. https:\/\/doi.org\/10.1001\/jamanetworkopen.2024.21846.","journal-title":"JAMA Netw Open"},{"key":"2355_CR123","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.fertnstert.2018.08.021","volume":"110","author":"LG Cooney","year":"2018","unstructured":"Cooney LG, Dokras A. Beyond fertility: polycystic ovary syndrome and long-term health. Fertil Steril. 2018;110:794\u2013809. https:\/\/doi.org\/10.1016\/j.fertnstert.2018.08.021.","journal-title":"Fertil Steril"},{"key":"2355_CR124","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/ijc.22034","volume":"119","author":"R Suzuki","year":"2006","unstructured":"Suzuki R, Rylander\u2010Rudqvist T, Ye W, Saji S, Wolk A. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: a prospective cohort study. Int J Cancer. 2006;119:1683\u20139. https:\/\/doi.org\/10.1002\/ijc.22034.","journal-title":"Int J Cancer"},{"key":"2355_CR125","doi-asserted-by":"publisher","DOI":"10.1186\/bcr998","volume":"7","author":"HJ Baer","year":"2005","unstructured":"Baer HJ, Colditz GA, Rosner B, Michels KB, Rich-Edwards JW, Hunter DJ, et al. Body fatness during childhood and adolescence and incidence of breast cancer in premenopausal women: a prospective cohort study. Breast Cancer Res. 2005;7:R314. https:\/\/doi.org\/10.1186\/bcr998.","journal-title":"Breast Cancer Res"},{"key":"2355_CR126","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1080\/14737159.2017.1340833","volume":"17","author":"K Mykhalchenko","year":"2017","unstructured":"Mykhalchenko K, Lizneva D, Trofimova T, Walker W, Suturina L, Diamond MP, et al. Genetics of polycystic ovary syndrome. Expert Rev Mol Diagn. 2017;17:723\u201333. https:\/\/doi.org\/10.1080\/14737159.2017.1340833.","journal-title":"Expert Rev Mol Diagn"},{"key":"2355_CR127","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41588-020-0609-2","volume":"52","author":"H Zhang","year":"2020","unstructured":"Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020;52:572\u201381. https:\/\/doi.org\/10.1038\/s41588-020-0609-2.","journal-title":"Nat Genet"},{"key":"2355_CR128","doi-asserted-by":"publisher","DOI":"10.1186\/s13058-024-01923-5","volume":"26","author":"K Bi","year":"2024","unstructured":"Bi K, Chen M, Zhao Q, Yang T, Xie W, Ma W, et al. The shared genetic landscape of polycystic ovary syndrome and breast cancer: convergence on ER\u2009+\u2009breast cancer but not ER- breast cancer. Breast Cancer Res. 2024;26:161. https:\/\/doi.org\/10.1186\/s13058-024-01923-5.","journal-title":"Breast Cancer Res"},{"key":"2355_CR129","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3390\/genes10020153","volume":"10","author":"VA Zavala","year":"2019","unstructured":"Zavala VA, Serrano-Gomez SJ, Dutil J, Fejerman L. Genetic epidemiology of breast cancer in Latin America. Genes (Basel). 2019;10:153. https:\/\/doi.org\/10.3390\/genes10020153.","journal-title":"Genes (Basel)"},{"key":"2355_CR130","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ajog.2021.03.020","volume":"225","author":"T Zhu","year":"2021","unstructured":"Zhu T, Cui J, Goodarzi MO. Polycystic ovary syndrome and breast cancer subtypes: a Mendelian randomization study. Am J Obstet Gynecol. 2021;225:99\u2013101. https:\/\/doi.org\/10.1016\/j.ajog.2021.03.020.","journal-title":"Am J Obstet Gynecol"},{"key":"2355_CR131","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10549-020-05973-z","volume":"185","author":"Y Wen","year":"2021","unstructured":"Wen Y, Wu X, Peng H, Li C, Jiang Y, Su Z, et al. Breast cancer risk in patients with polycystic ovary syndrome: a Mendelian randomization analysis. Breast Cancer Res Treat. 2021;185:799\u2013806. https:\/\/doi.org\/10.1007\/s10549-020-05973-z.","journal-title":"Breast Cancer Res Treat"},{"key":"2355_CR132","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.ajog.2020.05.016","volume":"223","author":"P-F Wu","year":"2020","unstructured":"Wu P-F, Li R-Z, Zhang W, Hu H-Y, Wang W, Lin Y. Polycystic ovary syndrome is causally associated with estrogen receptor\u2013positive instead of estrogen receptor\u2013negative breast cancer: a Mendelian randomization study. Am J Obstet Gynecol. 2020;223:583\u20135. https:\/\/doi.org\/10.1016\/j.ajog.2020.05.016.","journal-title":"Am J Obstet Gynecol"},{"key":"2355_CR133","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1093\/hmg\/6.3.397","volume":"6","author":"N Gharani","year":"1997","unstructured":"Gharani N, Waterworth DM, Batty S, White D, Gilling-Smith C, Conway GS, et al. Association of the steroid synthesis gene Cyp11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Genet. 1997;6:397\u2013402. https:\/\/doi.org\/10.1093\/hmg\/6.3.397.","journal-title":"Hum Mol Genet"},{"key":"2355_CR134","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1016\/S0015-0282(99)00628-7","volume":"73","author":"E Diamanti-Kandarakis","year":"2000","unstructured":"Diamanti-Kandarakis E, Bartzis MI, Bergiele AT, Tsianateli TC, Kouli CR. Microsatellite polymorphism (tttta)n at \u2212528 base pairs of gene CYP11\u03b1 influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril. 2000;73:735\u201341. https:\/\/doi.org\/10.1016\/S0015-0282(99)00628-7.","journal-title":"Fertil Steril"},{"key":"2355_CR135","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1158\/1055-9965.709.13.5","volume":"13","author":"W Zheng","year":"2004","unstructured":"Zheng W, Gao Y-T, Shu X-O, Wen W, Cai Q, Dai Q, et al. Population-based case-control study of CYP11A gene polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2004;13:709\u201314.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2355_CR136","doi-asserted-by":"publisher","first-page":"69520","DOI":"10.18632\/oncotarget.17846","volume":"8","author":"H Xu","year":"2017","unstructured":"Xu H, Han Y, Lou J, Zhang H, Zhao Y, Gy\u0151rffy B, et al. PDGFRA, HSD17B4 and HMGB2 are potential therapeutic targets in polycystic ovarian syndrome and breast cancer. Oncotarget. 2017;8:69520\u20136. https:\/\/doi.org\/10.18632\/oncotarget.17846.","journal-title":"Oncotarget"},{"key":"2355_CR137","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1080\/09513590.2020.1730794","volume":"36","author":"B Meczekalski","year":"2020","unstructured":"Meczekalski B, P\u00e9rez-Roncero GR, L\u00f3pez-Baena MT, Chedraui P, P\u00e9rez-L\u00f3pez FR. The polycystic ovary syndrome and gynecological cancer risk. Gynecol Endocrinol. 2020;36:289\u201393. https:\/\/doi.org\/10.1080\/09513590.2020.1730794.","journal-title":"Gynecol Endocrinol"},{"key":"2355_CR138","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.3390\/medicina59071338","volume":"59","author":"GMA Ajabnoor","year":"2023","unstructured":"Ajabnoor GMA. The molecular and genetic interactions between obesity and breast cancer risk. Medicina (B Aires). 2023;59:1338. https:\/\/doi.org\/10.3390\/medicina59071338.","journal-title":"Medicina (B Aires)"},{"key":"2355_CR139","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-015-0128-7","volume":"34","author":"F Planeix","year":"2015","unstructured":"Planeix F, Siraj M-A, Bidard F-C, Robin B, Pichon C, Sastre-Garau X, et al. Endothelial follicle-stimulating hormone receptor expression in invasive breast cancer and vascular remodeling at tumor periphery. J Exp Clin Cancer Res. 2015;34:12. https:\/\/doi.org\/10.1186\/s13046-015-0128-7.","journal-title":"J Exp Clin Cancer Res"},{"key":"2355_CR140","doi-asserted-by":"publisher","unstructured":"Yumiceba V, L\u00f3pez-Cort\u00e9s A, P\u00e9rez-Villa A, Yumiseba I, Guerrero S, Garc\u00eda-C\u00e1rdenas JM, et al. Oncology and Pharmacogenomics Insights in Polycystic Ovary Syndrome: An Integrative Analysis. Front Endocrinol (Lausanne). 2020;11. https:\/\/doi.org\/10.3389\/fendo.2020.585130.","DOI":"10.3389\/fendo.2020.585130"},{"key":"2355_CR141","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1177\/1933719114542015","volume":"22","author":"I Liaqat","year":"2015","unstructured":"Liaqat I, Jahan N, Krikun G, Taylor HS. Genetic polymorphisms in Pakistani women with polycystic ovary syndrome. Reprod Sci. 2015;22:347\u201357. https:\/\/doi.org\/10.1177\/1933719114542015.","journal-title":"Reprod Sci"},{"key":"2355_CR142","doi-asserted-by":"publisher","unstructured":"Jiao X, Chen W, Zhang J, Wang W, Song J, Chen D, et al. Variant Alleles of the ESR1, PPARG, HMGA2, and MTHFR Genes Are Associated With Polycystic Ovary Syndrome Risk in a Chinese Population: A Case-Control Study. Front Endocrinol (Lausanne). 2018;9. https:\/\/doi.org\/10.3389\/fendo.2018.00504.","DOI":"10.3389\/fendo.2018.00504"},{"key":"2355_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144560","volume":"741","author":"Z Douma","year":"2020","unstructured":"Douma Z, Dallel M, Bahia W, Ben Salem A, Hachani Ben Ali F, Almawi WY, et al. Association of estrogen receptor gene variants (ESR1 and ESR2) with polycystic ovary syndrome in Tunisia. Gene. 2020;741:144560. https:\/\/doi.org\/10.1016\/j.gene.2020.144560.","journal-title":"Gene"},{"key":"2355_CR144","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1007\/s11864-018-0542-0","volume":"19","author":"T Reinert","year":"2018","unstructured":"Reinert T, Gon\u00e7alves R, Bines J. Implications of ESR1 mutations in hormone receptor-positive breast cancer. Curr Treat Options Oncol. 2018;19:24. https:\/\/doi.org\/10.1007\/s11864-018-0542-0.","journal-title":"Curr Treat Options Oncol"},{"key":"2355_CR145","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejogrb.2018.05.027","volume":"227","author":"S Siddamalla","year":"2018","unstructured":"Siddamalla S, Reddy TV, Govatati S, Guruvaiah P, Deenadayal M, Shivaji S, et al. Influence of tumour suppressor gene (TP53, BRCA1 and BRCA2) polymorphisms on polycystic ovary syndrome in South Indian women. Eur J Obstet Gynecol Reprod Biol. 2018;227:13\u20138. https:\/\/doi.org\/10.1016\/j.ejogrb.2018.05.027.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2355_CR146","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1126\/science.1252230","volume":"343","author":"AR Venkitaraman","year":"2014","unstructured":"Venkitaraman AR. Cancer suppression by the chromosome custodians, BRCA1 and BRCA2. Science. 2014;343:1470\u20135. https:\/\/doi.org\/10.1126\/science.1252230.","journal-title":"Science"},{"key":"2355_CR147","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1177\/1947601911408889","volume":"2","author":"N Rivlin","year":"2011","unstructured":"Rivlin N, Brosh R, Oren M, Rotter V. Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis. Genes Cancer. 2011;2:466\u201374. https:\/\/doi.org\/10.1177\/1947601911408889.","journal-title":"Genes Cancer"},{"key":"2355_CR148","doi-asserted-by":"publisher","first-page":"1369","DOI":"10.12659\/MSM.890804","volume":"20","author":"I Yilmaz","year":"2014","unstructured":"Yilmaz I. Importance of metastatic lymph node ratio in non-metastatic, lymph node-invaded colon cancer: A clinical trial. Med Sci Monit. 2014;20:1369\u201375. https:\/\/doi.org\/10.12659\/MSM.890804.","journal-title":"Med Sci Monit"},{"key":"2355_CR149","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.pharmthera.2019.03.010","volume":"199","author":"E Cocco","year":"2019","unstructured":"Cocco E, Lopez S, Santin AD, Scaltriti M. Prevalence and role of HER2 mutations in cancer. Pharmacol Ther. 2019;199:188\u201396. https:\/\/doi.org\/10.1016\/j.pharmthera.2019.03.010.","journal-title":"Pharmacol Ther"},{"key":"2355_CR150","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1111\/cas.16148","volume":"115","author":"G Bon","year":"2024","unstructured":"Bon G, Fs DL, Filomeno L, Arcuri T, Krasniqi E, Pizzuti L, et al. HER2 mutation as an emerging target in advanced breast cancer. Cancer Sci. 2024;115:2147\u201358. https:\/\/doi.org\/10.1111\/cas.16148.","journal-title":"Cancer Sci"},{"key":"2355_CR151","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1038\/sj.bjc.6602557","volume":"92","author":"F Weber","year":"2005","unstructured":"Weber F, Fukino K, Sawada T, Williams N, Sweet K, Brena RM, et al. Variability in organ-specific EGFR mutational spectra in tumour epithelium and stroma may be the biological basis for differential responses to tyrosine kinase inhibitors. Br J Cancer. 2005;92:1922\u20136. https:\/\/doi.org\/10.1038\/sj.bjc.6602557.","journal-title":"Br J Cancer"},{"key":"2355_CR152","doi-asserted-by":"publisher","unstructured":"Zhang J-H, Zhan L, Zhao M-Y, Wang J-J, Xie F-F, Xu Z-Y, et al. Role of EGFR expressed on the granulosa cells in the pathogenesis of polycystic ovarian syndrome. Front Endocrinol (Lausanne). 2022;13. https:\/\/doi.org\/10.3389\/fendo.2022.971564.","DOI":"10.3389\/fendo.2022.971564"},{"key":"2355_CR153","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1159\/000508337","volume":"87","author":"YA Kariri","year":"2020","unstructured":"Kariri YA, Aleskandarany MA, Joseph C, Kurozumi S, Mohammed OJ, Toss MS, et al. Molecular complexity of lymphovascular invasion: the role of cell migration in breast cancer as a prototype. Pathobiology. 2020;87:218\u201331. https:\/\/doi.org\/10.1159\/000508337.","journal-title":"Pathobiology"},{"key":"2355_CR154","doi-asserted-by":"publisher","unstructured":"Yousif A K. The Role of Cell Cycle Division 6 (CDC6) in Cancer: Breast Cancer as a Prototype. International Journal of Pathology and Clinical Research 2024;10. https:\/\/doi.org\/10.23937\/2469-5807\/1510154.","DOI":"10.23937\/2469-5807\/1510154"},{"key":"2355_CR155","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10549-010-1108-4","volume":"124","author":"CM Coughlin","year":"2010","unstructured":"Coughlin CM, Johnston DS, Strahs A, Burczynski ME, Bacus S, Hill J, et al. Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy. Breast Cancer Res Treat. 2010;124:1\u201311. https:\/\/doi.org\/10.1007\/s10549-010-1108-4.","journal-title":"Breast Cancer Res Treat"},{"key":"2355_CR156","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.advenzreg.2009.10.015","volume":"50","author":"NR Leslie","year":"2010","unstructured":"Leslie NR, Spinelli L, Tibarewal P, Zilidis G, Weerasinghe N, Lim JC, et al. Indirect mechanisms of carcinogenesis via downregulation of PTEN function. Adv Enzyme Regul. 2010;50:112\u20138. https:\/\/doi.org\/10.1016\/j.advenzreg.2009.10.015.","journal-title":"Adv Enzyme Regul"},{"key":"2355_CR157","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3892\/ijmm.2017.2964","volume":"39","author":"C Hao","year":"2017","unstructured":"Hao C, Cui Y, Owen S, Li W, Cheng S, Jiang WG. Human osteopontin: potential clinical applications in cancer (review). Int J Mol Med. 2017;39:1327\u201337. https:\/\/doi.org\/10.3892\/ijmm.2017.2964.","journal-title":"Int J Mol Med"},{"key":"2355_CR158","doi-asserted-by":"publisher","unstructured":"Liang L, Lu G, Pan G, Deng Y, Liang J, Liang L, et al. A Case-Control Study of the Association Between the SPP1 Gene SNPs and the Susceptibility to Breast Cancer in Guangxi, China. Front Oncol. 2019;9. https:\/\/doi.org\/10.3389\/fonc.2019.01415.","DOI":"10.3389\/fonc.2019.01415"},{"key":"2355_CR159","doi-asserted-by":"publisher","first-page":"1438","DOI":"10.1016\/j.fertnstert.2006.04.027","volume":"86","author":"MR Jones","year":"2006","unstructured":"Jones MR, Italiano L, Wilson SG, Mullin BH, Mead R, Dudbridge F, et al. Polymorphism in HSD17B6 is associated with key features of polycystic ovary syndrome. Fertil Steril. 2006;86:1438\u201346. https:\/\/doi.org\/10.1016\/j.fertnstert.2006.04.027.","journal-title":"Fertil Steril"},{"key":"2355_CR160","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jsbmb.2008.12.012","volume":"114","author":"A Jansson","year":"2009","unstructured":"Jansson A. 17Beta-hydroxysteroid dehydrogenase enzymes and breast cancer. J Steroid Biochem Mol Biol. 2009;114:64\u20137. https:\/\/doi.org\/10.1016\/j.jsbmb.2008.12.012.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2355_CR161","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s10549-004-1200-8","volume":"88","author":"H Li","year":"2004","unstructured":"Li H, Cao D, Liu Y, Hou Y, Wu J, Lu J, et al. Prognostic value of matrix metalloproteinases (MMP-2 and MMP-9) in patients with lymph node-negative breast carcinoma. Breast Cancer Res Treat. 2004;88:75\u201385. https:\/\/doi.org\/10.1007\/s10549-004-1200-8.","journal-title":"Breast Cancer Res Treat"},{"key":"2355_CR162","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1111\/j.1365-2559.2007.02615.x","volume":"50","author":"E Mylona","year":"2007","unstructured":"Mylona E, Nomikos A, Magkou C, Kamberou M, Papassideri I, Keramopoulos A, et al. The clinicopathological and prognostic significance of membrane type 1 matrix metalloproteinase (MT1\u2010MMP) and MMP\u20109 according to their localization in invasive breast carcinoma. Histopathology. 2007;50:338\u201347. https:\/\/doi.org\/10.1111\/j.1365-2559.2007.02615.x.","journal-title":"Histopathology"},{"key":"2355_CR163","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.etap.2017.02.001","volume":"51","author":"Z Shen","year":"2017","unstructured":"Shen Z, Zhu D, Liu J, Chen J, Liu Y, Hu C, et al. 27-Hydroxycholesterol induces invasion and migration of breast cancer cells by increasing MMP9 and generating EMT through activation of STAT-3. Environ Toxicol Pharmacol. 2017;51:1\u20138. https:\/\/doi.org\/10.1016\/j.etap.2017.02.001.","journal-title":"Environ Toxicol Pharmacol"},{"key":"2355_CR164","doi-asserted-by":"publisher","first-page":"3700","DOI":"10.1002\/cncr.29552","volume":"121","author":"AJ White","year":"2015","unstructured":"White AJ, Nichols HB, Bradshaw PT, Sandler DP. Overall and central adiposity and breast cancer risk in the Sister Study. Cancer. 2015;121:3700\u20138. https:\/\/doi.org\/10.1002\/cncr.29552.","journal-title":"Cancer"},{"key":"2355_CR165","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.2337\/diacare.26.6.1752","volume":"26","author":"KB Michels","year":"2003","unstructured":"Michels KB, Solomon CG, Hu FB, Rosner BA, Hankinson SE, Colditz GA, et al. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses\u2019 Health Study. Diabetes Care. 2003;26:1752\u20138. https:\/\/doi.org\/10.2337\/diacare.26.6.1752.","journal-title":"Diabetes Care"},{"key":"2355_CR166","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1093\/humupd\/dmad015","volume":"29","author":"M Mill\u00e1n-de-Meer","year":"2023","unstructured":"Mill\u00e1n-de-Meer M, Luque-Ram\u00edrez M, Nattero-Ch\u00e1vez L, Escobar-Morreale HF. PCOS during the menopausal transition and after menopause: a systematic review and meta-analysis. Hum Reprod Update. 2023;29:741\u201372. https:\/\/doi.org\/10.1093\/humupd\/dmad015.","journal-title":"Hum Reprod Update"},{"key":"2355_CR167","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1007\/s10552-014-0376-4","volume":"25","author":"MM Gaudet","year":"2014","unstructured":"Gaudet MM, Carter BD, Patel AV, Teras LR, Jacobs EJ, Gapstur SM. Waist circumference, body mass index, and postmenopausal breast cancer incidence in the Cancer Prevention Study-II Nutrition Cohort. Cancer Causes Control. 2014;25:737\u201345. https:\/\/doi.org\/10.1007\/s10552-014-0376-4.","journal-title":"Cancer Causes Control"},{"key":"2355_CR168","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1001\/jamaoncol.2015.1546","volume":"1","author":"ML Neuhouser","year":"2015","unstructured":"Neuhouser ML, Aragaki AK, Prentice RL, Manson JE, Chlebowski R, Carty CL, et al. Overweight, obesity, and postmenopausal invasive breast cancer risk. JAMA Oncol. 2015;1:611. https:\/\/doi.org\/10.1001\/jamaoncol.2015.1546.","journal-title":"JAMA Oncol"},{"key":"2355_CR169","doi-asserted-by":"publisher","DOI":"10.4048\/jbc.2016.19.3.283","volume":"19","author":"F Sebastiani","year":"2016","unstructured":"Sebastiani F, Cortesi L, Sant M, Lucarini V, Cirilli C, De Matteis E, et al. Increased incidence of breast cancer in postmenopausal women with high body mass index at the Modena screening program. J Breast Cancer. 2016;19:283. https:\/\/doi.org\/10.4048\/jbc.2016.19.3.283.","journal-title":"J Breast Cancer"},{"key":"2355_CR170","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/s41416-024-02906-1","volume":"132","author":"W Wang","year":"2025","unstructured":"Wang W, Wang X, Jiang Y, Guo Y, Fu P, He W, et al. Normal weight obesity, circulating biomarkers and risk of breast cancer: a prospective cohort study and meta-analysis. Br J Cancer. 2025;132:203\u201311. https:\/\/doi.org\/10.1038\/s41416-024-02906-1.","journal-title":"Br J Cancer"},{"key":"2355_CR171","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.gendis.2019.09.006","volume":"8","author":"SS Mohanty","year":"2021","unstructured":"Mohanty SS, Mohanty PK. Obesity as potential breast cancer risk factor for postmenopausal women. Genes Dis. 2021;8:117\u201323. https:\/\/doi.org\/10.1016\/j.gendis.2019.09.006.","journal-title":"Genes Dis"},{"key":"2355_CR172","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1016\/S1470-2045(02)00849-5","volume":"3","author":"F Bianchini","year":"2002","unstructured":"Bianchini F, Kaaks R, Vainio H. Overweight, obesity, and cancer risk. Lancet Oncol. 2002;3:565\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(02)00849-5.","journal-title":"Lancet Oncol"},{"key":"2355_CR173","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s10549-020-05952-4","volume":"185","author":"JW Park","year":"2021","unstructured":"Park JW, Han K, Shin DW, Yeo Y, Chang JW, Yoo JE, et al. Obesity and breast cancer risk for pre- and postmenopausal women among over 6 million Korean women. Breast Cancer Res Treat. 2021;185:495\u2013506. https:\/\/doi.org\/10.1007\/s10549-020-05952-4.","journal-title":"Breast Cancer Res Treat"},{"key":"2355_CR174","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-025-01621-6","volume":"18","author":"P Su","year":"2025","unstructured":"Su P, Chen C, Sun Y. Physiopathology of polycystic ovary syndrome in endocrinology, metabolism and inflammation. J Ovarian Res. 2025;18:34. https:\/\/doi.org\/10.1186\/s13048-025-01621-6.","journal-title":"J Ovarian Res"},{"key":"2355_CR175","doi-asserted-by":"publisher","unstructured":"Wu D, Zhang Y, Wu C, An B, Wang X, Ni J, et al. The relationship between polycystic ovary syndrome and gynecological cancers: neurotransmitter metabolism changes and immune regulation. Front Immunol. 2025;16. https:\/\/doi.org\/10.3389\/fimmu.2025.1578470.","DOI":"10.3389\/fimmu.2025.1578470"},{"key":"2355_CR176","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1023\/A:1005740222307","volume":"16","author":"RA Walker","year":"1997","unstructured":"Walker RA, Jones JL, Chappell S, Walsh T, Shaw JA. Molecular pathology of breast cancer and its application to clinical management. Cancer Metastasis Rev. 1997;16:5\u201327. https:\/\/doi.org\/10.1023\/A:1005740222307.","journal-title":"Cancer Metastasis Rev"},{"key":"2355_CR177","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1093\/intimm\/dxaa078","volume":"33","author":"T Hirano","year":"2021","unstructured":"Hirano T. IL-6 in inflammation, autoimmunity and cancer. Int Immunol. 2021;33:127\u201348. https:\/\/doi.org\/10.1093\/intimm\/dxaa078.","journal-title":"Int Immunol"},{"key":"2355_CR178","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/S0015-0282(03)00502-8","volume":"80","author":"WU Atiomo","year":"2003","unstructured":"Atiomo WU, El-Mahdi E, Hardiman P. Familial associations in women with polycystic ovary syndrome. Fertil Steril. 2003;80:143\u20135. https:\/\/doi.org\/10.1016\/S0015-0282(03)00502-8.","journal-title":"Fertil Steril"},{"key":"2355_CR179","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s10815-009-9297-7","volume":"26","author":"A Moini","year":"2009","unstructured":"Moini A, Eslami B. Familial associations between polycystic ovarian syndrome and common diseases. J Assist Reprod Genet. 2009;26:123\u20137. https:\/\/doi.org\/10.1007\/s10815-009-9297-7.","journal-title":"J Assist Reprod Genet"},{"key":"2355_CR180","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1001\/archinte.166.22.2484","volume":"166","author":"KL Terry","year":"2006","unstructured":"Terry KL. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med. 2006;166:2484. https:\/\/doi.org\/10.1001\/archinte.166.22.2484.","journal-title":"Arch Intern Med"},{"key":"2355_CR181","doi-asserted-by":"publisher","first-page":"765","DOI":"10.6061\/clinics\/2015(11)09","volume":"70","author":"AS Melo","year":"2015","unstructured":"Melo AS, Ferriani RA, Navarro PA. Treatment of infertility in women with polycystic ovary syndrome: approach to clinical practice. Clinics Sao Paulo. 2015;70:765\u20139. https:\/\/doi.org\/10.6061\/clinics\/2015(11)09.","journal-title":"Clinics Sao Paulo"},{"key":"2355_CR182","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1080\/09513590.2021.1958310","volume":"37","author":"J Coll\u00e9e","year":"2021","unstructured":"Coll\u00e9e J, Mawet M, Tebache L, Nisolle M, Brichant G. Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments. Gynecol Endocrinol. 2021;37:869\u201374. https:\/\/doi.org\/10.1080\/09513590.2021.1958310.","journal-title":"Gynecol Endocrinol"},{"key":"2355_CR183","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1007\/s13224-018-1130-8","volume":"68","author":"SR Lindheim","year":"2018","unstructured":"Lindheim SR, Glenn TL, Smith MC, Gagneux P. Ovulation induction for the general gynecologist. J Obstet Gynaecol India. 2018;68:242\u201352. https:\/\/doi.org\/10.1007\/s13224-018-1130-8.","journal-title":"J Obstet Gynaecol India"},{"key":"2355_CR184","doi-asserted-by":"publisher","unstructured":"Vyrides AA, El Mahdi E, Giannakou K. Ovulation induction techniques in women with polycystic ovary syndrome. Front Med (Lausanne). 2022;9. https:\/\/doi.org\/10.3389\/fmed.2022.982230.","DOI":"10.3389\/fmed.2022.982230"},{"key":"2355_CR185","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.beem.2018.10.002","volume":"33","author":"AM Quaas","year":"2019","unstructured":"Quaas AM, Legro RS. Pharmacology of medications used for ovarian stimulation. Best Pract Res Clin Endocrinol Metab. 2019;33:21\u201333. https:\/\/doi.org\/10.1016\/j.beem.2018.10.002.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2355_CR186","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1136\/bmj.299.6694.309","volume":"299","author":"S Fishel","year":"1989","unstructured":"Fishel S, Jackson P. Follicular stimulation for high tech pregnancies: are we playing it safe? BMJ. 1989;299:309\u201311. https:\/\/doi.org\/10.1136\/bmj.299.6694.309.","journal-title":"BMJ"},{"key":"2355_CR187","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1093\/aje\/kwi084","volume":"161","author":"MD Althuis","year":"2005","unstructured":"Althuis MD. Uterine cancer after use of Clomiphene Citrate to induce ovulation. Am J Epidemiol. 2005;161:607\u201315. https:\/\/doi.org\/10.1093\/aje\/kwi084.","journal-title":"Am J Epidemiol"},{"key":"2355_CR188","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.fertnstert.2009.02.066","volume":"93","author":"BS Joo","year":"2010","unstructured":"Joo BS, Park SH, An BM, Kim KS, Moon SE, Moon HS. Serum estradiol levels during controlled ovarian hyperstimulation influence the pregnancy outcome of\u00a0in vitro fertilization in a concentration-dependent manner. Fertil Steril. 2010;93:442\u20136. https:\/\/doi.org\/10.1016\/j.fertnstert.2009.02.066.","journal-title":"Fertil Steril"},{"key":"2355_CR189","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.fertnstert.2012.04.019","volume":"98","author":"LM Stewart","year":"2012","unstructured":"Stewart LM, Holman CDJ, Hart R, Bulsara MK, Preen DB, Finn JC. In vitro fertilization and breast cancer: is there cause for concern? Fertil Steril. 2012;98:334\u201340. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.04.019.","journal-title":"Fertil Steril"},{"key":"2355_CR190","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1093\/aje\/kwn318","volume":"169","author":"R Calderon-Margalit","year":"2008","unstructured":"Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC, Manor O, et al. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol. 2008;169:365\u201375. https:\/\/doi.org\/10.1093\/aje\/kwn318.","journal-title":"Am J Epidemiol"},{"key":"2355_CR191","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/sj.bjc.6605086","volume":"100","author":"I dos Santos Silva","year":"2009","unstructured":"dos Santos Silva I, Wark PA, McCormack VA, Mayer D, Overton C, Little V, et al. Ovulation-stimulation drugs and cancer risks: a long-term follow-up of a British cohort. Br J Cancer. 2009;100:1824\u201331. https:\/\/doi.org\/10.1038\/sj.bjc.6605086.","journal-title":"Br J Cancer"},{"key":"2355_CR192","doi-asserted-by":"publisher","first-page":"809","DOI":"10.3109\/09513590.2012.671391","volume":"28","author":"L-G Liat","year":"2012","unstructured":"Liat L-G, Jaron R, Liraz O, Tzvia B, Shlomo M, Bruno L. Are infertility treatments a potential risk factor for cancer development? Perspective of 30 years of follow-up. Gynecol Endocrinol. 2012;28:809\u201314. https:\/\/doi.org\/10.3109\/09513590.2012.671391.","journal-title":"Gynecol Endocrinol"},{"key":"2355_CR193","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/j.fertnstert.2013.08.008","volume":"100","author":"B Trabert","year":"2013","unstructured":"Trabert B, Lamb EJ, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, et al. Ovulation-inducing drugs and ovarian cancer risk: results from an extended follow-up of a large United States infertility cohort. Fertil Steril. 2013;100:1660\u20136. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.08.008.","journal-title":"Fertil Steril"},{"key":"2355_CR194","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1056\/NEJM199409223311204","volume":"331","author":"MA Rossing","year":"1994","unstructured":"Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Ovarian tumors in a cohort of infertile women. N Engl J Med. 1994;331:771\u20136. https:\/\/doi.org\/10.1056\/NEJM199409223311204.","journal-title":"N Engl J Med"},{"key":"2355_CR195","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1093\/aje\/kwh315","volume":"160","author":"MA Rossing","year":"2004","unstructured":"Rossing MA. A case-control study of ovarian cancer in relation to infertility and the use of ovulation-inducing drugs. Am J Epidemiol. 2004;160:1070\u20138. https:\/\/doi.org\/10.1093\/aje\/kwh315.","journal-title":"Am J Epidemiol"},{"key":"2355_CR196","doi-asserted-by":"publisher","first-page":"2005","DOI":"10.1093\/humrep\/deh371","volume":"19","author":"LA Brinton","year":"2004","unstructured":"Brinton LA. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod. 2004;19:2005\u201313. https:\/\/doi.org\/10.1093\/humrep\/deh371.","journal-title":"Hum Reprod"},{"key":"2355_CR197","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1093\/humrep\/der322","volume":"26","author":"FE van Leeuwen","year":"2011","unstructured":"van Leeuwen FE, Klip H, Mooij TM, van de Swaluw AMG, Lambalk CB, Kortman M, et al. Risk of borderline and invasive ovarian tumours after ovarian stimulation for in vitro fertilization in a large Dutch cohort. Hum Reprod. 2011;26:3456\u201365. https:\/\/doi.org\/10.1093\/humrep\/der322.","journal-title":"Hum Reprod"},{"key":"2355_CR198","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1158\/1055-9965.EPI-16-0809","volume":"26","author":"MM Reigstad","year":"2017","unstructured":"Reigstad MM, Storeng R, Myklebust T\u00c5, Oldereid NB, Omland AK, Robsahm TE, et al. Cancer risk in women treated with fertility drugs according to parity status\u2014a registry-based cohort study. Cancer Epidemiol Biomarkers Prev. 2017;26:953\u201362. https:\/\/doi.org\/10.1158\/1055-9965.EPI-16-0809.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2355_CR199","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1158\/1055-9965.EPI-07-0075","volume":"16","author":"A Jensen","year":"2007","unstructured":"Jensen A, Sharif H, Svare EI, Frederiksen K, Kj\u00e6r SK. Risk of Breast Cancer After Exposure to Fertility Drugs: Results from a Large Danish Cohort Study. Cancer Epidemiol Biomark Prev. 2007;16:1400\u20137. https:\/\/doi.org\/10.1158\/1055-9965.EPI-07-0075.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2355_CR200","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1093\/humrep\/deh422","volume":"19","author":"E Gauthier","year":"2004","unstructured":"Gauthier E, Paoletti X, Clavel-Chapelon F. Breast cancer risk associated with being treated for infertility: results from the French E3N cohort study. Hum Reprod. 2004;19:2216\u201321. https:\/\/doi.org\/10.1093\/humrep\/deh422.","journal-title":"Hum Reprod"},{"key":"2355_CR201","doi-asserted-by":"publisher","first-page":"72.e1","DOI":"10.1016\/j.ajog.2008.08.066","volume":"200","author":"CC Org\u00e9as","year":"2009","unstructured":"Org\u00e9as CC, Sanner K, Hall P, Conner P, Holte J, Nilsson SJ, et al. Breast cancer incidence after hormonal infertility treatment in Sweden: a cohort study. Am J Obstet Gynecol. 2009;200:72.e1-72.e7. https:\/\/doi.org\/10.1016\/j.ajog.2008.08.066.","journal-title":"Am J Obstet Gynecol"},{"key":"2355_CR202","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1158\/1055-9965.EPI-13-0996","volume":"23","author":"LA Brinton","year":"2014","unstructured":"Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Niwa S, Ruggieri D, et al. Long-term Relationship of Ovulation-Stimulating Drugs to Breast Cancer Risk. Cancer Epidemiol Biomark Prev. 2014;23:584\u201393. https:\/\/doi.org\/10.1158\/1055-9965.EPI-13-0996.","journal-title":"Cancer Epidemiol Biomark Prev"},{"key":"2355_CR203","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/S0015-0282(02)04950-6","volume":"79","author":"RT Burkman","year":"2003","unstructured":"Burkman RT, Tang M-TC, Malone KE, Marchbanks PA, McDonald JA, Folger SG. Infertility drugs and the risk of breast cancer: findings from the National Institute of Child Health and Human Development Women\u2019s Contraceptive and Reproductive Experiences Study. Fertil Steril. 2003;79:844\u201351. https:\/\/doi.org\/10.1016\/S0015-0282(02)04950-6.","journal-title":"Fertil Steril"},{"key":"2355_CR204","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/jnci\/djs255","volume":"104","author":"C Fei","year":"2012","unstructured":"Fei C, DeRoo LA, Sandler DP, Weinberg CR. Fertility drugs and young-onset breast cancer: results from the Two Sister Study. JNCI J Natl Cancer Inst. 2012;104:1021\u20137. https:\/\/doi.org\/10.1093\/jnci\/djs255.","journal-title":"JNCI J Natl Cancer Inst"},{"key":"2355_CR205","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0301-2115(01)00344-X","volume":"98","author":"A Benshushan","year":"2001","unstructured":"Benshushan A, Paltiel O, Brzezinski A, Tanos V, Barchana M, Shoshani O, et al. Ovulation induction and risk of endometrial cancer: a pilot study. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2001;98:53\u20137. https:\/\/doi.org\/10.1016\/S0301-2115(01)00344-X.","journal-title":"European Journal of Obstetrics & Gynecology and Reproductive Biology"},{"key":"2355_CR206","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1016\/j.fertnstert.2015.06.045","volume":"104","author":"LA Brinton","year":"2015","unstructured":"Brinton LA, Moghissi KS, Scoccia B, Lamb EJ, Trabert B, Niwa S, et al. Effects of fertility drugs on cancers other than breast and gynecologic malignancies. Fertil Steril. 2015;104:980\u20138. https:\/\/doi.org\/10.1016\/j.fertnstert.2015.06.045.","journal-title":"Fertil Steril"},{"key":"2355_CR207","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/humrep\/dem381","volume":"23","author":"CG Hannibal","year":"2007","unstructured":"Hannibal CG, Jensen A, Sharif H, Kjaer SK. Risk of thyroid cancer after exposure to fertility drugs: results from a large Danish cohort study. Hum Reprod. 2007;23:451\u20136. https:\/\/doi.org\/10.1093\/humrep\/dem381.","journal-title":"Hum Reprod"},{"key":"2355_CR208","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/humrep\/dev023","volume":"30","author":"M Spaan","year":"2015","unstructured":"Spaan M, van den Belt-Dusebout AW, Schaapveld M, Mooij TM, Burger CW, van Leeuwen FE, et al. Melanoma risk after ovarian stimulation for in vitro fertilization. Hum Reprod. 2015;30:1216\u201328. https:\/\/doi.org\/10.1093\/humrep\/dev023.","journal-title":"Hum Reprod"},{"key":"2355_CR209","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/00008390-200110000-00015","volume":"11","author":"P Young","year":"2001","unstructured":"Young P, Purdie D, Jackman L, Molloy D, Green A. A study of infertility treatment and melanoma. Melanoma Res. 2001;11:535\u201341. https:\/\/doi.org\/10.1097\/00008390-200110000-00015.","journal-title":"Melanoma Res"},{"key":"2355_CR210","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1016\/0026-0495(94)90209-7","volume":"43","author":"EM Velazquez","year":"1994","unstructured":"Velazquez EM, Mendoza S, Hamer T, Sosa F, Glueck CJ. Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism. 1994;43:647\u201354. https:\/\/doi.org\/10.1016\/0026-0495(94)90209-7.","journal-title":"Metabolism"},{"key":"2355_CR211","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1210\/er.2008-0030","volume":"30","author":"S Palomba","year":"2009","unstructured":"Palomba S, Falbo A, Zullo F, Orio F. Evidence-based and potential benefits of metformin in the polycystic ovary syndrome: a comprehensive review. Endocr Rev. 2009;30:1\u201350. https:\/\/doi.org\/10.1210\/er.2008-0030.","journal-title":"Endocr Rev"},{"key":"2355_CR212","doi-asserted-by":"publisher","DOI":"10.1186\/s13048-022-01091-0","volume":"16","author":"H Zhao","year":"2023","unstructured":"Zhao H, Zhang J, Cheng X, Nie X, He B. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023;16:9. https:\/\/doi.org\/10.1186\/s13048-022-01091-0.","journal-title":"J Ovarian Res"},{"key":"2355_CR213","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1080\/09513590500476164","volume":"22","author":"AD Genazzani","year":"2006","unstructured":"Genazzani AD, Strucchi C, Luisi M, Casarosa E, Lanzoni C, Baraldi E, et al. Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22:36\u201343. https:\/\/doi.org\/10.1080\/09513590500476164.","journal-title":"Gynecol Endocrinol"},{"key":"2355_CR214","doi-asserted-by":"publisher","unstructured":"Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH. Metformin for ovulation induction (excluding gonadotrophins) in women with polycystic ovary syndrome. Cochrane Database of Systematic Reviews 2019;2019. https:\/\/doi.org\/10.1002\/14651858.CD013505.","DOI":"10.1002\/14651858.CD013505"},{"key":"2355_CR215","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejogrb.2022.01.025","volume":"271","author":"R Magzoub","year":"2022","unstructured":"Magzoub R, Kheirelseid EAH, Perks C, Lewis S. Does metformin improve reproduction outcomes for non-obese, infertile women with polycystic ovary syndrome? Meta-analysis and systematic review. Eur J Obstet Gynecol Reprod Biol. 2022;271:38\u201362. https:\/\/doi.org\/10.1016\/j.ejogrb.2022.01.025.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2355_CR216","doi-asserted-by":"publisher","first-page":"197","DOI":"10.3181\/00379727-105-26054","volume":"105","author":"DE Holtkamp","year":"1960","unstructured":"Holtkamp DE, Greslin JG, Root CA, Lerner LJ. Gonadotrophin inhibiting and anti-fecundity effects of chloramiphene. Exp Biol Med Maywood. 1960;105:197\u2013201. https:\/\/doi.org\/10.3181\/00379727-105-26054.","journal-title":"Exp Biol Med Maywood"},{"key":"2355_CR217","doi-asserted-by":"publisher","unstructured":"Brown J, Farquhar C, Beck J, Boothroyd C, Hughes E. Clomiphene and anti-oestrogens for ovulation induction in PCOS. In: Brown J, editor. Cochrane Database of Systematic Reviews, Chichester, UK: John Wiley & Sons, Ltd; 2009. https:\/\/doi.org\/10.1002\/14651858.CD002249.pub4.","DOI":"10.1002\/14651858.CD002249.pub4"},{"key":"2355_CR218","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1210\/jc.2014-4235","volume":"100","author":"S Palomba","year":"2015","unstructured":"Palomba S. Aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab. 2015;100:1742\u20137. https:\/\/doi.org\/10.1210\/jc.2014-4235.","journal-title":"J Clin Endocrinol Metab"},{"key":"2355_CR219","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.fertnstert.2013.05.033","volume":"100","author":"Practice Committee of the American Society for Reproductive Medicine","year":"2013","unstructured":"Practice Committee of the American Society for Reproductive Medicine. Use of clomiphene citrate in infertile women: a committee opinion. Fertil Steril. 2013;100:341\u20138. https:\/\/doi.org\/10.1016\/j.fertnstert.2013.05.033.","journal-title":"Fertil Steril"},{"key":"2355_CR220","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/BF03347527","volume":"27","author":"S Palomba","year":"2004","unstructured":"Palomba S, Orio F, Russo T, Falbo A, Cascella T, Colao A, et al. Is ovulation induction still a therapeutic problem in patients with polycystic ovary syndrome? J Endocrinol Invest. 2004;27:796\u2013805. https:\/\/doi.org\/10.1007\/BF03347527.","journal-title":"J Endocrinol Invest"},{"key":"2355_CR221","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S0015-0282(00)01705-2","volume":"75","author":"MFM Mitwally","year":"2001","unstructured":"Mitwally MFM, Casper RF. Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate. Fertil Steril. 2001;75:305\u20139. https:\/\/doi.org\/10.1016\/S0015-0282(00)01705-2.","journal-title":"Fertil Steril"},{"key":"2355_CR222","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1056\/NEJMoa1313517","volume":"371","author":"RS Legro","year":"2014","unstructured":"Legro RS, Brzyski RG, Diamond MP, Coutifaris C, Schlaff WD, Casson P, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med. 2014;371:119\u201329. https:\/\/doi.org\/10.1056\/NEJMoa1313517.","journal-title":"N Engl J Med"},{"key":"2355_CR223","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1093\/humupd\/dmz029","volume":"25","author":"R Wang","year":"2019","unstructured":"Wang R, Li W, Bordewijk EM, Legro RS, Zhang H, Wu X, et al. First-line ovulation induction for polycystic ovary syndrome: an individual participant data meta-analysis. Hum Reprod Update. 2019;25:717\u201332. https:\/\/doi.org\/10.1093\/humupd\/dmz029.","journal-title":"Hum Reprod Update"},{"key":"2355_CR224","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/AOG.0000000000005070","volume":"141","author":"Z Liu","year":"2023","unstructured":"Liu Z, Geng Y, Huang Y, Hu R, Li F, Song Y, et al. Letrozole compared with Clomiphene Citrate for Polycystic Ovarian Syndrome. Obstet Gynecol. 2023;141:523\u201334. https:\/\/doi.org\/10.1097\/AOG.0000000000005070.","journal-title":"Obstet Gynecol"},{"key":"2355_CR225","doi-asserted-by":"publisher","DOI":"10.1186\/s12958-023-01113-6","volume":"21","author":"S Palomba","year":"2023","unstructured":"Palomba S, Costanzi F, Nelson SM, Caserta D, Humaidan P. Interventions to prevent or reduce the incidence and severity of Ovarian Hyperstimulation Syndrome: a systematic umbrella review of the best clinical evidence. Reprod Biol Endocrinol. 2023;21:67. https:\/\/doi.org\/10.1186\/s12958-023-01113-6.","journal-title":"Reprod Biol Endocrinol"},{"key":"2355_CR226","doi-asserted-by":"publisher","unstructured":"Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, Kolibianakis E, et al. ESHRE guideline: ovarian stimulation for IVF\/ICSI\u2020. Hum Reprod Open 2020;2020. https:\/\/doi.org\/10.1093\/hropen\/hoaa009.","DOI":"10.1093\/hropen\/hoaa009"},{"key":"2355_CR227","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1210\/clinem\/dgad463","volume":"108","author":"HJ Teede","year":"2023","unstructured":"Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023;108:2447\u201369. https:\/\/doi.org\/10.1210\/clinem\/dgad463.","journal-title":"J Clin Endocrinol Metab"},{"key":"2355_CR228","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/S0015-0282(16)40156-1","volume":"25","author":"JF Richards","year":"1974","unstructured":"Richards JF, Griffith DR. Effect of Cis- and Trans-Clomiphene on mammary gland development in the rat. Fertil Steril. 1974;25:74\u20138. https:\/\/doi.org\/10.1016\/S0015-0282(16)40156-1.","journal-title":"Fertil Steril"},{"key":"2355_CR229","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3109\/10799893.2014.951895","volume":"35","author":"J Elloumi-Mseddi","year":"2015","unstructured":"Elloumi-Mseddi J, Jemel-Oualha I, Beji A, Hakim B, Aifa S. Effect of estradiol and clomiphene citrate on Erk activation in breast cancer cells. J Recept Signal Transduct. 2015;35:202\u20136. https:\/\/doi.org\/10.3109\/10799893.2014.951895.","journal-title":"J Recept Signal Transduct"},{"key":"2355_CR230","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1093\/humrep\/der378","volume":"27","author":"A Cooley","year":"2012","unstructured":"Cooley A, Matthews L, Zelivianski S, Hardy A, Jeruss JS. Effect of infertility treatment and pregnancy-related hormones on breast cell proliferation in vitro. Hum Reprod. 2012;27:146\u201352. https:\/\/doi.org\/10.1093\/humrep\/der378.","journal-title":"Hum Reprod"},{"key":"2355_CR231","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1007\/s43032-025-01884-w","volume":"32","author":"O Roy","year":"2025","unstructured":"Roy O, Ammankallu S, Narayana VK, Narayana C, Hebbar S, Adiga PK, et al. Mass spectrometric analysis of Clomiphene Citrate-induced changes in the secretome profile of PAX8-positive human Fallopian tube secretory epithelial cells and identification of biomarkers relevant to reproduction and pregnancy. Reprod Sci. 2025;32:2423\u201341. https:\/\/doi.org\/10.1007\/s43032-025-01884-w.","journal-title":"Reprod Sci"},{"key":"2355_CR232","first-page":"4177","volume":"50","author":"LJ Lerner","year":"1990","unstructured":"Lerner LJ, Jordan VC. Development of antiestrogens and their use in breast cancer: eighth Cain Memorial Award lecture. Cancer Res. 1990;50:4177\u201389.","journal-title":"Cancer Res"},{"issue":"10","key":"2355_CR233","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/0014-2964(74)90114-5","volume":"1974","author":"E Hecker","year":"1965","unstructured":"Hecker E, Vegh I, Levy CM, Magin CA, Martinez JC, Loureiro J, et al. Clinical trial of clomiphene in advanced breast cancer. Eur J Cancer. 1965;1974(10):747\u20139. https:\/\/doi.org\/10.1016\/0014-2964(74)90114-5.","journal-title":"Eur J Cancer"},{"key":"2355_CR234","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.fertnstert.2021.01.044","volume":"116","author":"Y Beebeejaun","year":"2021","unstructured":"Beebeejaun Y, Athithan A, Copeland TP, Kamath MS, Sarris I, Sunkara SK. Risk of breast cancer in women treated with ovarian stimulation drugs for infertility: a systematic review and meta-analysis. Fertil Steril. 2021;116:198\u2013207. https:\/\/doi.org\/10.1016\/j.fertnstert.2021.01.044.","journal-title":"Fertil Steril"},{"key":"2355_CR235","doi-asserted-by":"publisher","unstructured":"Cullinane C, Gillan H, Geraghty J, Evoy D, Rothwell J, McCartan D, et al. Fertility treatment and breast-cancer incidence: meta-analysis. BJS Open. 2022;6. https:\/\/doi.org\/10.1093\/bjsopen\/zrab149.","DOI":"10.1093\/bjsopen\/zrab149"},{"key":"2355_CR236","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1016\/j.fertnstert.2012.12.029","volume":"99","author":"LA Brinton","year":"2013","unstructured":"Brinton LA, Trabert B, Shalev V, Lunenfeld E, Sella T, Chodick G. In vitro fertilization and risk of breast and gynecologic cancers: a retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril. 2013;99:1189\u201396. https:\/\/doi.org\/10.1016\/j.fertnstert.2012.12.029.","journal-title":"Fertil Steril"},{"key":"2355_CR237","doi-asserted-by":"publisher","first-page":"1620","DOI":"10.2337\/dc08-2175","volume":"32","author":"G Libby","year":"2009","unstructured":"Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JMM. New users of metformin are at low risk of incident cancer. Diabetes Care. 2009;32:1620\u20135. https:\/\/doi.org\/10.2337\/dc08-2175.","journal-title":"Diabetes Care"},{"key":"2355_CR238","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.2337\/dc09-1791","volume":"33","author":"M Bodmer","year":"2010","unstructured":"Bodmer M, Meier C, Kr\u00e4henb\u00fchl S, Jick SS, Meier CR. Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care. 2010;33:1304\u20138. https:\/\/doi.org\/10.2337\/dc09-1791.","journal-title":"Diabetes Care"},{"key":"2355_CR239","doi-asserted-by":"publisher","first-page":"2844","DOI":"10.1200\/JCO.2011.39.7505","volume":"30","author":"RT Chlebowski","year":"2012","unstructured":"Chlebowski RT, McTiernan A, Wactawski-Wende J, Manson JE, Aragaki AK, Rohan T, et al. Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol. 2012;30:2844\u201352. https:\/\/doi.org\/10.1200\/JCO.2011.39.7505.","journal-title":"J Clin Oncol"},{"key":"2355_CR240","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1136\/bmj.38415.708634.F7","volume":"330","author":"JMM Evans","year":"2005","unstructured":"Evans JMM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. Metformin and reduced risk of cancer in diabetic patients. BMJ. 2005;330:1304\u20135. https:\/\/doi.org\/10.1136\/bmj.38415.708634.F7.","journal-title":"BMJ"},{"key":"2355_CR241","doi-asserted-by":"publisher","first-page":"3576","DOI":"10.1038\/sj.onc.1211024","volume":"27","author":"SI Ben","year":"2008","unstructured":"Ben SI, Laurent K, Loubat A, Giorgetti-Peraldi S, Colosetti P, Auberger P, et al. The antidiabetic drug metformin exerts an antitumoral effect in vitro and in vivo through a decrease of cyclin D1 level. Oncogene. 2008;27:3576\u201386. https:\/\/doi.org\/10.1038\/sj.onc.1211024.","journal-title":"Oncogene"},{"key":"2355_CR242","doi-asserted-by":"publisher","first-page":"909","DOI":"10.4161\/cc.8.6.7933","volume":"8","author":"IN Alimova","year":"2009","unstructured":"Alimova IN, Liu B, Fan Z, Edgerton SM, Dillon T, Lind SE, et al. Metformin inhibits breast cancer cell growth, colony formation and induces cell cycle arrest in vitro. Cell Cycle. 2009;8:909\u201315. https:\/\/doi.org\/10.4161\/cc.8.6.7933.","journal-title":"Cell Cycle"},{"key":"2355_CR243","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.1093\/aje\/kwz157","volume":"188","author":"R Dankner","year":"2019","unstructured":"Dankner R, Agay N, Olmer L, Murad H, Keinan Boker L, Balicer RD, et al. Metformin treatment and cancer risk: Cox regression analysis, with time-dependent covariates, of 320,000 persons with incident diabetes mellitus. Am J Epidemiol. 2019;188:1794\u2013800. https:\/\/doi.org\/10.1093\/aje\/kwz157.","journal-title":"Am J Epidemiol"},{"key":"2355_CR244","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s10549-019-05185-0","volume":"175","author":"M Hosio","year":"2019","unstructured":"Hosio M, Urpilainen E, Marttila M, Hautakoski A, Arffman M, Sund R, et al. Association of antidiabetic medication and statins with breast cancer incidence in women with type 2 diabetes. Breast Cancer Res Treat. 2019;175:741\u20138. https:\/\/doi.org\/10.1007\/s10549-019-05185-0.","journal-title":"Breast Cancer Res Treat"},{"key":"2355_CR245","doi-asserted-by":"publisher","first-page":"11703","DOI":"10.1002\/cam4.5545","volume":"12","author":"Y Lu","year":"2023","unstructured":"Lu Y, Hajjar A, Cryns VL, Trentham-Dietz A, Gangnon RE, Heckman-Stoddard BM, et al. Breast cancer risk for women with diabetes and the impact of metformin: a meta-analysis. Cancer Med. 2023;12:11703\u201318. https:\/\/doi.org\/10.1002\/cam4.5545.","journal-title":"Cancer Med"},{"key":"2355_CR246","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s10815-020-01709-6","volume":"37","author":"G Nayak","year":"2020","unstructured":"Nayak G, Salian SR, Agarwal P, Suresh Poojary P, Rao A, Kumari S, et al. Antidiabetic drug metformin affects the developmental competence of cleavage-stage embryos. J Assist Reprod Genet. 2020;37:1227\u201338. https:\/\/doi.org\/10.1007\/s10815-020-01709-6.","journal-title":"J Assist Reprod Genet"},{"key":"2355_CR247","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123416","volume":"363","author":"C Velazquez","year":"2025","unstructured":"Velazquez C, Herrero Y, Prost K, Bordaquievich M, Neira M, Parborell F, et al. Reproductive outcomes in female mice offspring due to maternal metformin treatment. Life Sci. 2025;363:123416. https:\/\/doi.org\/10.1016\/j.lfs.2025.123416.","journal-title":"Life Sci"},{"key":"2355_CR248","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbadis.2024.167258","volume":"1870","author":"S Francisca","year":"2024","unstructured":"Francisca S, Gloria A-F, Marco P-B, Camila N-C, V\u00edctor C, Bredford K. Metformin exposure during pregnancy and lactation affects offspring\u2019s long-term body weight and adipose tissue mass independent of the maternal metabolic state. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 2024;1870:167258. https:\/\/doi.org\/10.1016\/j.bbadis.2024.167258.","journal-title":"Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease"},{"key":"2355_CR249","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.151507","volume":"753","author":"S Ursavas","year":"2025","unstructured":"Ursavas S, Kuyucu Y, Yenilmez ED, Tuli A, Tekayev M, Mete UO. The evaluation of the effects of metformin on the rat testes at a light and electron microscopic level. Biochem Biophys Res Commun. 2025;753:151507. https:\/\/doi.org\/10.1016\/j.bbrc.2025.151507.","journal-title":"Biochem Biophys Res Commun"},{"key":"2355_CR250","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1530\/REP-15-0565","volume":"151","author":"M Faure","year":"2016","unstructured":"Faure M, Guibert E, Alves S, Pain B, Ram\u00e9 C, Dupont J, et al. The insulin sensitiser metformin regulates chicken Sertoli and germ cell populations. Reproduction. 2016;151:527\u201338. https:\/\/doi.org\/10.1530\/REP-15-0565.","journal-title":"Reproduction"},{"key":"2355_CR251","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2024.117039","volume":"490","author":"AN Kunnath","year":"2024","unstructured":"Kunnath AN, Parker SK, Crasta DN, Kunhiraman JP, Madhvacharya VV, Kumari S, et al. Metformin augments major cytoplasmic organization except for spindle organization in oocytes cultured under hyperglycemic and hyperlipidemic conditions: an in vitro study. Toxicol Appl Pharmacol. 2024;490:117039. https:\/\/doi.org\/10.1016\/j.taap.2024.117039.","journal-title":"Toxicol Appl Pharmacol"},{"key":"2355_CR252","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1016\/j.fertnstert.2015.07.1135","volume":"104","author":"B Luke","year":"2015","unstructured":"Luke B, Brown MB, Spector LG, Missmer SA, Leach RE, Williams M, et al. Cancer in women after assisted reproductive technology. Fertil Steril. 2015;104:1218\u201326. https:\/\/doi.org\/10.1016\/j.fertnstert.2015.07.1135.","journal-title":"Fertil Steril"},{"key":"2355_CR253","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1001\/jama.2016.9389","volume":"316","author":"AW van den Belt-Dusebout","year":"2016","unstructured":"van den Belt-Dusebout AW, Spaan M, Lambalk CB, Kortman M, Laven JSE, van Santbrink EJP, et al. Ovarian Stimulation for In Vitro Fertilization and Long-term Risk of Breast Cancer. JAMA. 2016;316:300. https:\/\/doi.org\/10.1001\/jama.2016.9389.","journal-title":"JAMA"},{"key":"2355_CR254","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.fertnstert.2017.05.010","volume":"108","author":"FE Lundberg","year":"2017","unstructured":"Lundberg FE, Iliadou AN, Rodriguez-Wallberg K, Bergh C, Gemzell-Danielsson K, Johansson ALV. Ovarian stimulation and risk of breast cancer in Swedish women. Fertil Steril. 2017;108:137\u201344. https:\/\/doi.org\/10.1016\/j.fertnstert.2017.05.010.","journal-title":"Fertil Steril"},{"key":"2355_CR255","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1093\/humrep\/deab270","volume":"37","author":"R Machtinger","year":"2022","unstructured":"Machtinger R, Fallach N, Goldstein I, Chodick G, Schiff E, Orvieto R, et al. Ovarian stimulation for fertility treatments and risk of breast cancer: a matched cohort study. Hum Reprod. 2022;37:577\u201385. https:\/\/doi.org\/10.1093\/humrep\/deab270.","journal-title":"Hum Reprod"},{"key":"2355_CR256","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1016\/S0140-6736(99)05203-4","volume":"354","author":"A Venn","year":"1999","unstructured":"Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. The Lancet. 1999;354:1586\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(99)05203-4.","journal-title":"The Lancet"},{"key":"2355_CR257","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1245\/s10434-007-9800-2","volume":"15","author":"I Pappo","year":"2008","unstructured":"Pappo I, Lerner-Geva L, Halevy A, Olmer L, Friedler S, Raziel A, et al. The possible association between IVF and breast cancer incidence. Ann Surg Oncol. 2008;15:1048\u201355. https:\/\/doi.org\/10.1245\/s10434-007-9800-2.","journal-title":"Ann Surg Oncol"},{"key":"2355_CR258","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1093\/humrep\/deab219","volume":"36","author":"D Vassard","year":"2021","unstructured":"Vassard D, Pinborg A, Kamper-J\u00f8rgensen M, Lyng Forman J, Glazer CH, Kroman N, et al. Assisted reproductive technology treatment and risk of breast cancer: a population-based cohort study. Hum Reprod. 2021;36:3152\u201360. https:\/\/doi.org\/10.1093\/humrep\/deab219.","journal-title":"Hum Reprod"},{"key":"2355_CR259","doi-asserted-by":"publisher","unstructured":"Williams CL, Jones ME, Swerdlow AJ, Botting BJ, Davies MC, Jacobs I, et al. Risks of ovarian, breast, and corpus uteri cancer in women treated with assisted reproductive technology in Great Britain, 1991\u20132010: data linkage study including 2.2 million person years of observation. BMJ. 2018:k2644. https:\/\/doi.org\/10.1136\/bmj.k2644.","DOI":"10.1136\/bmj.k2644"}],"container-title":["Reproductive Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12978-026-02355-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-026-02355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12978-026-02355-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:03:40Z","timestamp":1784185420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12978-026-02355-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":259,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2355"],"URL":"https:\/\/doi.org\/10.1186\/s12978-026-02355-4","relation":{},"ISSN":["1742-4755"],"issn-type":[{"value":"1742-4755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"7 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"138"}}